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Research Snapshot 44 
Research Question: This systematic review update with meta-analyses, in adult cancer 45 
patients receiving chemotherapy, aims to determine: what are the effects of ginger 46 
supplementation dose and duration on the incidence and severity of chemotherapy-induced 47 
nausea and vomiting (CINV) and outcomes related to CINV (e.g. quality of life, fatigue, 48 
adverse events), compared to placebo or standard anti-emetic medication? 49 
 3 
Key Findings: Eighteen papers were analysed. The likelihood of acute vomiting was reduced 50 
by 60% with ginger supplementation of ≤1g/day for >3-days duration, compared to control 51 
groups (OR: 0.4; 95% CI: 0.17-0.81; P=0.01). The likelihood of fatigue was reduced by 80% 52 
with ginger supplementation of any dose for <3-days duration (OR: 0.2; 95% CI: 0.03-0.87; 53 
P=0.03). No statistically significant association was found between ginger and likelihood of 54 
overall or delayed vomiting, likelihood or severity of nausea, or other outcomes related to 55 
CINV. 56 
  57 
 4 
Abstract  58 
Background: Ginger has been proposed as an adjuvant treatment for chemotherapy-induced 59 
nausea and vomiting (CINV).  60 
Objective: The aim of this systematic review with meta-analyses is to evaluate, in adult cancer 61 
patients receiving chemotherapy, the effects of ginger supplementation dose and duration on 62 
the incidence, duration, and severity of CINV and outcomes related to CINV (quality of life, 63 
fatigue), compared to placebo or standard anti-emetic medication. 64 
Method: Five electronic databases were searched from database inception to April 2018. The 65 
quality of evidence was appraised with the Cochrane Risk of Bias tool and GRADE. Data were 66 
pooled using Revman. 67 
Results: Eighteen papers were analysed. The likelihood of acute vomiting was reduced by 60% 68 
with ginger supplementation of ≤1g/day for >3-days duration, compared to control groups (OR: 69 
0.4; 95% CI: 0.17-0.81; P=0.01; n=3 studies; n=3 interventions; n=301 participants; I2=20%; 70 
GRADE level: moderate). The likelihood of fatigue was reduced by 80% with ginger 71 
supplementation of any dose for <3-days duration (OR: 0.2; 95% CI: 0.03-0.87; P=0.03; n=1 72 
studies; n=2 interventions; n=219 participants; I2=0%; GRADE level: low). No statistically 73 
significant association was found between ginger and likelihood of overall or delayed vomiting, 74 
likelihood or severity of nausea, or other outcomes related to CINV. 75 
Conclusions: Ginger supplementation might benefit chemotherapy-induced vomiting as well 76 
as fatigue. Due to clinical heterogeneity, this systematic review update found no association 77 
between ginger and chemotherapy-induced nausea and other CINV-related outcomes. The 78 
results of this systematic review and meta-analysis provide a rationale for further research with 79 
stronger study designs, adequate sample sizes, standardized ginger products, and validated 80 
outcome measures to confirm efficacy of ginger supplementation and optimal dosing regimens.  81 
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Introduction 82 
Nausea and vomiting are among the most distressing side effects of chemotherapy (CTx).1,2 83 
Chemotherapy is a common and effective treatment for cancer; however, chemotherapy-84 
induced nausea and vomiting (CINV) can affect treatment completion as it is known to 85 
exacerbate fatigue, anxiety and depression,3 as well as decrease quality of life (QoL) and food 86 
intake.4-7 Consequently, CINV is attributable to 50-60% of CTx patients experiencing protein-87 
energy malnutrition as a result of failing to meet nutritional requirements,8 which further 88 
compromises treatment outcomes.9 Good management of CINV is therefore a priority to 89 
optimize treatment efficacy, QoL, and subsequent survival.4-6 90 
Anti-emetics to prevent and manage CINV are often prescribed in combination, with the 91 
precise regimen tailored to the emetogenicity of the CTx and patient characteristics.10  92 
Consensus between the three main clinical guidelines for anti-emetic prescription suggests the 93 
administration of a serotonin (5-HT3) receptor antagonist and dexamethasone for moderately 94 
emetogenic CTx regimens (those with 30-90% risk of emesis), with the addition of a neurokinin 95 
1 (NK1) receptor antagonist for patients receiving highly emetogenic CTx (>90% risk of 96 
emesis).11,12 Despite pharmacological developments with combination anti-emetics, CINV 97 
remains a problematic side effect of CTx.13  98 
Ginger (Zingiber officinale) is a traditional remedy for nausea and vomiting in many cultures 99 
and has been investigated for use in motion sickness, morning sickness, and post-operative 100 
nausea.14 More novel is the role of ginger for the prevention and management of CINV.15,16 101 
The exact mechanism remains unclear; however, beneficial effects are thought to be due to the 102 
effects of gingerol and shogaol compounds on multiple components of CINV pathways.17 The 103 
most well understood pathway is ginger’s antagonistic effect on 5-HT3 receptors. Ginger non-104 
competitively inhibits 5-HT3 receptor activation in humans via binding at a site that is different 105 
from other types of 5-HT3 receptor antagonists.18 Therefore, synergistic inhibition of 5-HT3 106 
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signalling might occur when ginger is combined with other 5-HT3 antagonists, for example 107 
ondansetron, a common anti-emetic administered during CTx, suggesting there are additional 108 
beneficial effects when ginger is included in anti-emetic regimens.17,19 Ginger is also thought 109 
to render beneficial effects through its antagonistic effect on muscarinic and histaminergic 110 
receptors; its ability to regulate gastric emptying and gastrointestinal motility; and its role in 111 
reducing oxidative stress and inflammation.17 These multiple pathways may also be linked with 112 
other CINV-related symptoms such as fatigue, anxiety, and depression, thereby impacting 113 
overall health-related quality of life.3,17,20-22 114 
Two systematic reviews, both published in 2013,15,16 explored the effect of ginger on CINV. 115 
The first review identified seven clinical studies that investigated supplemental ginger to treat 116 
CINV.15 Qualitative examination of included studies was used by Marx et al.15 to conclude that 117 
the available literature provided mixed support for the use of ginger, not warranting standard 118 
recommendations for its use in the clinical setting. The second review identified five double-119 
blind placebo-controlled randomized trials for inclusion, and meta-analysis determined no 120 
significant association between ginger and the control of CINV.16 However, both reviews 121 
highlighted major limitations in existing research in terms of study design with non-122 
standardized CTx and anti-emetic regimens, inconsistent and/or inadequate ginger intervention 123 
dose and duration, as well as failure to identify or control potentially confounding variables.15,16  124 
Due to the inconclusive nature of the previous systematic reviews15,16 and more recent 125 
publication of clinical trials that examine the effect of ginger on CINV, an updated review of 126 
the literature was warranted. The aim of this systematic review update with meta-analyses was 127 
to evaluate, in adult cancer patients receiving CTx, the effects of ginger supplementation dose 128 
and duration on the incidence and severity of CINV and outcomes related to CINV (quality of 129 
life, fatigue), compared to placebo or standard anti-emetic medication. 130 
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Method 131 
This systematic review was reported according to the Preferred Reporting Items for Systematic 132 
Reviews and Meta-analyses (PRISMA) statement.23 The study protocol was registered with the 133 
International Prospective Register of Systematic Reviews (PROSPERO number: 134 
CRD42017077022).  135 
Search Strategy 136 
PubMed, the Cochrane Library, and CINAHL databases were previously searched by the 137 
authors from database inception up until April 2012 to locate both parallel and crossover 138 
intervention trials. The findings of that search were reported by Marx et al.15 For this update, 139 
these databases were searched to locate studies published from April 2012 to April 2018 with 140 
the addition of two databases: Embase and Web of Science, which were searched from database 141 
inception to 19 September 2017. The search strategy used for this updated review was similarly 142 
based upon the following terms: (ginger* OR zingiber officinale) AND (cancer* OR 143 
chemotherap*) AND (nausea OR vomit*) AND (randomized controlled trial OR intervention). 144 
The search strategy was designed in PubMed using a combination of keywords and controlled 145 
vocabulary and translated to other databases with Polyglot24 (full search strategy is shown in 146 
Online Supplementary Material 1). A snowballing search was also used, whereby reference 147 
lists of included studies and previous systematic and narrative reviews were considered to 148 
identify additional studies not found in the systematic search strategy up until 4 April 2018. 149 
Initial screening of titles and abstracts, as well as full-text screening, were completed by two 150 
investigators independently (MC and SM). Disagreement between reviewers was resolved by 151 
discussion with a third researcher (WM).  152 
Selection of studies 153 
Studies published in any language were included in this review if they provided an intervention 154 
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of ginger supplementation in any form to adult (mean sample age ≥18 years) human 155 
participants undergoing CTx for cancer and had used a control of either placebo or anti-emetic 156 
medication. Studies were excluded if the population of interest was receiving concurrent 157 
radiation therapy, which is a known predictive factor for nausea and vomiting. Studies were 158 
included if participants were undergoing other therapies such as surgery, biologics, 159 
immunotherapy, and bone marrow transplant therapy. Non-English language studies were also 160 
excluded if they could not be translated to English with Google Translate software.25  The 161 
primary outcomes of interest were CINV incidence (number of participants who reported 162 
nausea and/or vomiting of any severity) and nausea severity (measured using any tool). 163 
Secondary outcomes were patient QoL, fatigue, anxiety or depression, adverse events (any 164 
reported side effects relatable to the intervention), adherence to the intervention, stomach 165 
dysrhythmia, tachygastria or bradygastria, nutritional status, dietary intake, health service use, 166 
health care costs, and mortality. 167 
Data extraction and review of study quality 168 
Data extraction and individual study quality assessment using the Cochrane Risk of Bias Tool15 169 
were carried out independently on all studies, including eligible studies identified in the review 170 
by Marx et al., by two authors (MC and [WM or SM]), with disagreements managed by 171 
consensus.  172 
The certainty in the body of evidence for each outcome of interest was classified by the Grading 173 
of Recommendations, Assessment, Development and Evaluation (GRADE) approach26  with 174 
the software GRADEpro GDT [GRADEpro Guideline Development Tool, McMaster 175 
University, 2015 (developed by Evidence Prime, Inc)]. Four levels of certainty for the 176 
estimated effect were utilized by the GRADE assessment: very low (very little confidence), 177 
low (limited confidence), moderate (moderately confident), and high (very confident). The 178 
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GRADE level of evidence was determined by review and discussion amongst three authors 179 
(MC, SM, and WM).  180 
Meta-analysis 181 
Where two or more interventions reported the same outcome with sufficient incidence or mean 182 
and variance data, outcomes for the intervention and control group were pooled by meta-183 
analysis using Revman.27 The overall effect size was calculated by combining all the individual 184 
studies’ outcome data and associated 95% confidence interval (CI) to calculate an odds ratio 185 
or mean difference using the standard random effects method in Revman. The pooled 186 
categorical outcomes were reported as odds ratios (OR; ratio of the odds of the outcome in the 187 
two groups of interest) with 95% confidence intervals, using the Mantel-Haenszel test. The 188 
inverse variance test pooled continuous outcomes, which were reported as mean differences 189 
(MD) where the same tool and scale was used, or the standardized mean difference (SMD) 190 
where different measurement scales or tools for the same construct were used. To support 191 
clinical interpretation, SMDs were re-expressed into a scale of one of the included 192 
measurement tools by multiplying the SMD effect size by the standard deviation of the tool’s 193 
scale in the total sample.28 Heterogeneity was evaluated with the I2 statistic, with >50% 194 
representative of substantial heterogeneity.29 A P value of less than 0.05 was considered the 195 
cut off for statistical significance. When meta-analyses included 10 or more studies, a funnel 196 
plot was generated by Revman to assess publication bias. If there was a non-significant trend 197 
or substantial heterogeneity, sensitivity analyses were undertaken with study factors such as 198 
participant characteristics, study design, study quality, and intervention/confounding variables. 199 
Additionally, to identify the effect of various dosing regimens, subgroup analyses were 200 
performed. Due to conflicting optimal dosing regimens and duration of intervention in the 201 
literature, interventions were divided as evenly as possible which generated the daily dosing 202 
categories of ≤1g / >1g and duration categories of ≤3 / >3 days.  Therefore, subgroup analyses 203 
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were undertaken using four groups: 1) short intervention duration (≤3 days per CTx cycle) with 204 
low dose (≤1g/day); 2) short intervention duration (≤3 days per CTx cycle) with high dose of 205 
ginger (>1g/day); 3) long intervention duration (>3 days per CTx cycle) and low dose of ginger 206 
(≤1g/day); 4) long intervention duration (>3 days per CTx cycle) and high dose of ginger 207 
(>1g/day). Additionally, it was hypothesized that ginger could have varying levels of efficacy 208 
for anticipatory (prior to CTx), acute (≤24 hours post CTx), and delayed (>24 hours post CTx) 209 
CINV; therefore, separate analyses were performed for each.   210 
Results 211 
Search results and study quality 212 
The search strategy and study selection process that led to the 18 studies included in this review 213 
are displayed in Figure 1. A total of 13 papers were analysed in nine meta-analyses. Figure 2 214 
indicates that risk of bias across all papers was mostly low, with all but four papers included 215 
having low risk of bias for at least four of the seven domains (justifications are shown in Online 216 
Supplementary Material 2). However, the majority of papers had an unclear or high risk of bias 217 
for allocation concealment, mainly due to papers failing to provide a description of 218 
concealment procedures. Two papers,30,31 which reported nausea outcomes only, had poor 219 
study quality due to >70% of Cochrane Risk of Bias domains rated as unclear or high risk of 220 
bias. Due to the small number of studies in each meta-analysis, publication bias could not be 221 
assessed. 222 
Intervention characteristics 223 
Characteristics of the 18 included studies are summarized in Table 1 and shown in detail in 224 
Online Supplementary Material 3. Konmun et al.32 and Danwilai et al.33 reported different 225 
outcomes in each paper; however, they refer to the same study and intervention. One study had 226 
two intervention arms34 and another had three intervention arms;35 therefore, a total of 20 227 
interventions are referred to in this review.  228 
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The active constituents in the ginger interventions were specified in ten interventions. 229 
Combined gingerols, zingerone, and shogoals of an unspecified dose were used in three 230 
interventions;35 gingerols (ranging from 11-16 mg) and shogoal (ranging from 0.92-1.12 mg) 231 
were used in four interventions;34,36-38 and gingerols (ranging from 0.5-150 mg) alone were 232 
administered in three interventions.32,33,38,39 Adherence to the prescribed supplements ranged 233 
from 71%39 to 97%40 with no significant difference between intervention and control groups.  234 
Study samples 235 
Sample sizes ranged from  n=2041 to n=37535 (n=1,652 total participants; 64% female) and are 236 
reported in detail in Online Supplementary Material 3. Participants in eight studies were 237 
administered platinum-based CTx with or without other CTx agents,32,33,36,38,42-45 six were 238 
administered anthracycline-based CTx,31-33,40,45,46 and six studies did not specify the CTx 239 
agents administered to participants.30,34,35,37,39,47 Six studies reported patients received single-240 
day CTx treatments,34,36,37,39,47 while the remaining studies did not specify days of CTx 241 
treatment. Participants in 13 studies were administered a corticosteroid in combination with a 242 
5-HT3 receptor antagonist;31-33,35-37,40-44,46,47 and seven were administered additional anti-243 
emetics.31,32,36,40,43,44,47 244 
Efficacy of ginger supplementation for nausea and vomiting outcomes  245 
 246 
Table 2 contains all meta-analyses conducted for primary and secondary outcomes. Forest plots 247 
for all non-significant meta-analyses are shown in Online Supplementary Material 4 and 248 
justifications for the all GRADE levels are shown in Online Supplementary Material 5. In terms 249 
of primary outcomes, the only significant finding was for duration of >3 days of 250 
supplementation with doses ≤1g/day which reduced the likelihood of acute vomiting by 60% 251 
(Figure 3). Results regarding anticipatory CINV were unable to be pooled due to lack of studies 252 
that reported this outcome. Only one study reported results related to anticipatory nausea, 253 
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finding no significant difference in likelihood of anticipatory nausea between control and 254 
intervention groups.36 However, it is unclear whether participants in this study were consuming 255 
the intervention at the time of anticipatory nausea being measured (at day 21 or 28 prior to 256 
commencing subsequent CTx cycles). Only one study reported results related to anticipatory 257 
vomiting, which found significantly higher incidence among the control group compared to 258 
those who received ginger supplementation (IG n=0.5/40 (SD 0.3); CG n=1.5/40 (SD 5.9); 259 
P=0.04).37 260 
In terms of secondary outcomes, three of the four studies32,38,39 that reported data on QoL found 261 
a statistically significant difference in QoL scores between control and intervention groups at 262 
the end of the study period, favouring ginger intervention over control, however, no significant 263 
association was found with meta-analysis (Table 2). The only significant findings in regards to 264 
fatigue were identified with sensitivity analysis, which found ginger supplementation of any 265 
dose for ≤3-days reduced likelihood of fatigue by 80% (Figure 4). No studies reported 266 
outcomes on anxiety and depression; stomach dysrhythmia, tachygastria or bradygastria; 267 
nutrition status; dietary intake; health service use; or health care costs. 268 
Seven studies reported on events believed to be directly attributable to the intervention.33,35-269 
39,43 Of these, three provided adequate data for meta-analysis, finding ginger supplementation 270 
of any dose for any duration significantly increased likelihood of any gastrointestinal, flushing, 271 
rash-related, or unspecified adverse event (Figure 5). Reported gastrointestinal symptoms 272 
potentially relatable to the study intervention included dry mouth, heartburn, reflux, 273 
constipation and diarrhoea; however, due to insufficient data for meta-analysis, only the results 274 
on heartburn were able to be pooled, finding no association between ginger supplementation 275 
of any dose for any duration and likelihood of heartburn. Studies reported no significant 276 
differences between adverse events not directly attributable to the intervention, which included 277 
neutropenia and other unspecified biochemical markers, restlessness, headache, and heart 278 
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palpitations. Two studies reported incidence of mortality, with no statistically significant 279 
difference reported between intervention and control groups.44,45 280 
Discussion 281 
This systematic review update with meta-analyses provides the most current and 282 
comprehensive meta-analysis to date exploring the use of ginger for CTx patients. Consistent 283 
with conclusions made in the previous two systematic reviews on the topic,48,49 ginger 284 
supplementation in conjunction with standard anti-emetic care could be beneficial for CTx-285 
induced vomiting and CINV-related outcomes. Although there is low to very low certainty in 286 
the estimated effect size, ginger supplementation is suggested to have large beneficial effects 287 
on likelihood of acute vomiting, as well as small but significant improvements on fatigue 288 
among individuals receiving CTx. Findings remain inconclusive as to whether ginger benefits 289 
delayed CTx-induced vomiting, CTx-induced nausea, and QoL.   290 
Despite most papers that reported on nausea incidence favouring ginger supplementation over 291 
comparator interventions,30,38,42,45,46,50 the pooled estimate found no association with no 292 
statistical heterogeneity (I2=0%), therefore there is some confidence in this finding.  However, 293 
meta-analyses results in regards to likelihood of nausea appear to be skewed by one larger 294 
study.36 Therefore, ginger supplementation for improvements in nausea incidence cannot yet 295 
be disregarded as a treatment option due to the substantially large clinical heterogeneity 296 
between studies.  297 
The non-significant finding which favoured control for nausea severity, particularly for delayed 298 
nausea severity when administered for ≤3-days, was driven by only two studies;34,42 which 299 
were the only studies included in the model after sensitivity analysis. Although there was no 300 
statistical heterogeneity, there was substantial clinical, as well as only a small number of studies 301 
included which used a range of un-validated outcome evaluation questionnaires.  302 
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This review found low confidence that supplementation of ≤1g/day of ginger for >3-days, 303 
starting on Day 1 of CTx reduces likelihood of vomiting by 20-70%; where other dosing 304 
regimens were found to have no significant association. Uncertainty in regards to the ideal 305 
ginger dosage is likely due to the clinical heterogeneity. Ginger supplementation of ≤1g/day 306 
for >3-days potentially reduces likelihood of overall vomiting by 50% (OR: 0.5; 95% CI: 0.21-307 
1.13) and delayed vomiting by 70% (OR: 0.3; 95% CI: 0.10-1.13); however, the results were 308 
not significant at p<0.05, likely attributable to significant clinical heterogeneity among 309 
included studies. The only statistically significant finding that ginger administration for >3-310 
days benefited acute vomiting is conflicting, as only ginger consumed prior to and within the 311 
first 24-hours is applicable to acute symptoms (i.e. symptoms within the first 24 hours). This 312 
unlikely finding is further evidence of the impact of clinical heterogeneity leading to decreased 313 
confidence in the results, suggesting that until further well-designed studies with homogenous 314 
or well-controlled samples are available, all results should be considered with caution, 315 
including those with no statistical heterogeneity.  316 
In terms of dosage frequency, research suggests ginger should be distributed at least four times 317 
across the day rather than once or twice daily due to ginger’s short elimination half-life of ≤2 318 
hours.51 However, most studies in this review administered ginger only once or twice per day, 319 
which suggests the effects of ginger may be underestimated. Furthermore, the delivery method 320 
of ginger administered may also affect the half-life. Although the half-life of ginger is short, 321 
production of ginger-induced intestinal microbiota metabolites may be a suggested mechanism 322 
for reducing activation of CINV pathways.17,52,53   323 
This was the first systematic review to explore additional CINV-related outcomes, finding that 324 
ginger resulted in beneficial effects outside of the direct CINV pathways. A decrease in fatigue 325 
was seen with ginger administration, a common and problematic symptom otherwise difficult 326 
to treat and manage.54 The decrease may be due to ginger’s proposed anti-inflammatory effects, 327 
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as inflammation is a pathway for fatigue,17,20-22 however, none of the included studies examined 328 
inflammatory markers. Further studies are needed to build confidence in the body of evidence 329 
for the effect of ginger on other CINV-related outcomes.  330 
Adherence to the intervention was found to be high overall and no different to placebo groups, 331 
implying that ginger supplementation as an additional medication is feasible and does not 332 
impose any additional factors which might prevent adherence. Although this review found 333 
ginger did not cause serious adverse events and therefore could be considered safe, it should 334 
be noted that there was poor reporting of adverse events in most studies as well as a failure to 335 
distinguish events reasonably relatable to the intervention. Although statistically significant 336 
results were obtained to suggest likelihood of adverse events is higher among individuals 337 
administered ginger, the adverse events were mild. Meta-analysis suggested that the likelihood 338 
of heartburn, a commonly reported side effect of ginger, did not differ between the study groups. 339 
Mortality, arguably the most serious adverse event, also did not appear to differ between study 340 
groups in the limited number of studies that reported this event.  341 
Limitations in the literature 342 
Although a substantial number of new studies were identified in this systematic review update, 343 
the included studies are clinically heterogeneous, which decreases confidence in the results and 344 
contributes to the large number analyses which had insufficient evidence to reject the null 345 
hypothesis. Sources of clinical heterogeneity were varying CTx and anti-emetic regimens as 346 
well as cancer types and participant samples. In addition, substantial clinical heterogeneity was 347 
introduced through lack of reporting of, or large variations across studies in ginger 348 
interventions; specifically, the composition of active constituents, dosing frequencies and 349 
delivery methods. Sensitivity analysis was able to be explored for study quality and overall 350 
ginger dosing regimens, but other sources of clinical heterogeneity could not be accounted for 351 
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and publication bias was not able to be assessed. Furthermore, this review was limited by the 352 
small number of available studies that reported the outcomes of interest.   353 
Directions for future research 354 
The results of this systematic review and meta-analysis provide a rationale for further research 355 
such as that which is currently underway.55 In line with recommendations from the previous 356 
systematic review,48 additional randomized controlled trials with adequate sample sizes, 357 
standardized ginger products, use of validated outcome measures, and full reporting of data 358 
would better inform the evidence regarding the type of ginger supplement that should be 359 
recommended and the most effective dosing schedule. Study designs should also measure 360 
adverse events potentially relatable to the ginger intervention to determine the safety of the 361 
intervention. Other CTx-related outcomes that are associated with CINV need to be assessed, 362 
including anxiety and depression, stomach dysrhythmia, and tachygastria or bradygastria. 363 
Other factors that need evaluation related to overall health include nutrition status, dietary 364 
intake, health service use, and health care costs. Patients receiving multi-day CTx regimens 365 
should be included in studies before recommending ginger products to all patients receiving 366 
CTx. The potential mechanisms of action of ginger having beneficial effects on CINV 367 
pathways also need investigation. 368 
Conclusion 369 
Ginger supplementation can potentially benefit CTx-induced vomiting as well as fatigue. Due 370 
to clinical heterogeneity, this systematic review update with meta-analyses found no 371 
association between ginger and CTx-induced nausea or other CINV-related outcomes. The 372 
results of this systematic review and meta-analysis provide a rationale for further research using 373 
stronger study designs, adequate sample sizes, standardized ginger products, and validated 374 
outcome measures to confirm efficacy of ginger supplementation and optimal dosing regimens.375 
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Table 1. Summary of intervention characteristics and study samples of the 18 included studies in this systematic review with meta-analyses aiming 590 
to evaluate, in adult cancer patients receiving chemotherapy, the effects of ginger supplementation dose and duration on the incidence and severity 591 
of chemotherapy-induced nausea and vomiting and outcomes related to chemotherapy-induced nausea and vomiting (quality of life, fatigue). 592 
Citation Country Study Design Sample 
Size 
CTX 
emetogenicity 
Anti-emetic 
Use (Yes/No) 
Intervention Intervention dose Intervention duration Comparator  
Alparslan  
2012 30 
Turkey Non-RCT N=45 Not specified Not specified Tablet 
(ginger type unspecified) 
1.6g/d  
(2x 0.4g BD) 
Entire treatment duration IV antiemetic  
Arslan  
2015 31 
Turkey RCT N=60 Not specified Yes  Sachet  
(powdered ginger root on 
yoghurt) 
1g/d  
(0.5g BD) 
3 days; from 30 mins 
before Cycle 1 Day 1 
Standard care 
Bossi  
2017 36 
Italy Double blind placebo 
RCT 
N=251 High Yes 
 
Capsule 
(liquid ginger root extract) 
0.16g/d  
(2x 0.04g BD) 
42-56 days; from Day 2 of 
each Cycle 
Placebo 
Danwilai  
2017 33 
Thailand Pilot double blind 
placebo RCT 
N=50 Moderate or 
high 
Yes  Capsule 
(powdered ginger root 
extract) 
0.02g/d  
(2x0.005g BD) 
From 3 days prior to Cycle 
1 Day 1 through to Cycle 4 
Placebo 
Fahimi  
2011 42 
Iran Double blind 
crossover placebo 
RCT 
N=50 Not specified Yes Capsule 
(powdered ginger root 
extract) 
1g  
(2x 0.25g BD) 
3 days; from Cycle 1 Day 
1, then a 3-week washout 
period 
Placebo 
Konmun  
2017 32 
Thaliand Double blind placebo 
RCT 
N=88 Moderate or 
high 
Yes Capsule 
(type unspecified) 
0.02g/d  
(2x0.005g BD) 
From 3 days prior to CTx 
Day 1 for at least 3 Cycles 
Placebo 
Li  
2018 38 
China Double blind placebo 
RCT 
N=146 Moderate or 
high 
Yes Capsule 
(powdered ginger root 
extract) 
0.5g/d  
(2x0.25g BD) 
5 days; from CTx Day 1 Placebo 
Manusirivithaya 
2004 43 
Thaliand Double blind 
crossover RCT 
N=48 High Yes Capsule 
(powdered ginger root 
extract) 
1g  
(0.25g QID) 
5 days; then a 3-4 week 
washout period 
Placebo 
Marx  Australia Double blind placebo 
RCT 
N=51 Not specified Yes Capsule 1.2g  5 days; from CTx Day 1 Placebo 
 23 
2017 39 (powdered ginger root 
extract) 
(0.3g QID) 
Montazeri  
2013 44 
Iran Crossover double 
blind placebo RCT 
N=44 Not specified Yes Capsule 
(powdered ginger root 
extract) 
1g/d  
(2x 0.25g BD) 
For one Cycle (at least 28 
days) before crossing over 
Placebo 
Muthia  
2013 41 
Indonesia Control time series N=20 Not specified Yes Drink 
(type unspecified) 
1 serve  
(QID) 
Not specified Standard care 
Panahi  
2012 46 
Iran Open pilot RCT N=100 Moderate or 
high 
Yes 
 
Capsule 
(powdered ginger root 
extract) 
1.5g  
(0.5g TID) 
5 days; from CTx Day 1 Placebo 
Ryan  
2012 35 
USA Double blind placebo 
RCT 
N=371 Any Yes Capsule 
(liquid ginger root extract) 
0.5g/d  
(2x0.25g) 
6 days; from 3 days before 
CTx Day 1 
Placebo 
   N=375 Any Yes 
 
Capsule 
(liquid ginger root extract) 
1g/d  
(4x 0.25g) 
6 days; from 3 days before 
CTx Day 1 
Placebo 
   N=375 Any Yes 
 
Capsule 
(liquid ginger root extract) 
1.5g/d  
(6x 0.25g). 
6 days; from 3 days before 
CTx Day 1 
Placebo 
Sanaati  
2016 47 
Iran Double blind RCT N=43 Not specified Yes Capsule 
(powdered ginger root 
extract) 
1g/d  
(0.5g BD) 
10 days; from 5 days 
before CTx Day 1 
Standard care 
Shokri  
2017 45 
Iran Double blind placebo 
RCT 
N=49 Not specified Not specified Capsule 
(type unspecified) 
2g/d  
(1g BD) 
For 6 Cycles Placebo  
Thamlikitkul 
2017 40 
Thailand Double blind 
crossover placebo 
RCT 
N=34 High Yes Capsule 
(powdered ginger root 
extract) 
1g  
(0.5g BD) 
5 days; from CTx Day 1 Placebo 
Yekta  
2012 37 
Iran Double blind placebo 
RCT 
N=98 Any Yes Capsule 
(powdered ginger root 
extract) 
1g  
(0.25g QID) 
6 days; from 3 days before 
CTx Day 1 
Placebo 
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Zick  
2009 34 
USA Double blind placebo 
RCT 
N=110 Any Yes Capsule 
(powdered ginger root 
extract) 
1g/d  
(4x 0.25g) 
3 days; from CTx Day 1  Placebo 
   N=109 Any Yes Capsule 
(powdered ginger root 
extract) 
2g/d  
(8x 0.25g) 
3 days; from CTx Day 1 Placebo 
CTX: chemotherapy; RCT: randomised controlled trial; IV: intravenous; BD: twice daily; QID: four times daily; TID: three times daily 593 
 594 
 595 
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Table 2. Results from meta-analyses conducted  to evaluate, in adult cancer patients 
receiving chemotherapy, the effects of ginger supplementation dose and duration on the 
incidence and severity of chemotherapy-induced nausea and vomiting and outcomes 
related to chemotherapy-induced nausea and vomiting (quality of life, fatigue). 
 
Outcome Pooled 
estimate 
Significance 
of pooled 
estimate 
Heterogeneity 
(I2) 
Number 
of 
interven-
tions 
Sample 
Size 
GRADE 
level 
Nausea incidence 
Overall nausea incidence:a 
any dose, any duration 
OR: 1.0,  
95% CI:  
0.74-1.28 
P=0.82b 0%c 8 883 moderate 
Acute nausea incidence: 
any dose, any duration 
OR: 0.8,  
95% CI:  
0.47-1.42 
P=0.47b 63% 6 590 very low 
Delayed nausea incidence:a 
any dose, any duration 
OR: 0.9,  
95% CI:  
0.65-1.30 
P=0.64b 28% 7 834 moderate 
Nausea Severity 
Overall nausea severity: 
any dose, any duration 
SMD: 0.2,  
95% CI:  
-0.02-0.38 
P=0.08 0%c 3 378 low 
Acute nausea severity: 
any dose, any duration 
SMD: 0,  
95% CI:  
-0.17-0.23 
P=0.76b 0% 5 438 low 
Delayed nausea severity: 
any dose, any duration 
SMD: 0.4,  
95% CI:  
-0.07-0.77 
P=0.10b 75% 4 378 very low 
Vomiting Incidence 
Overall vomiting incidence:a 
any dose, any duration 
OR: 0.8,  
95% CI:  
0.44-1.36 
P=0.38 66% 9 825 very low 
Acute vomiting incidence: 
any dose, any duration 
OR: 0.7,  
95% CI:  
0.38-1.24 
P=0.22 57% 7 671 Very low 
Acute vomiting incidence: 
≤ 1g/day dose, >3 days duration 
OR: 0.4;  
95% CI:  
0.17-0.81 
P=0.01 20% 3 301 moderate 
 26 
Delayed vomiting incidence:a 
any dose, any duration 
OR: 0.8,  
95% CI:  
0.39-1.79 
P=0.63 76% 7 671 very low 
Secondary Outcomes 
Quality of Life: 
any dose, any duration 
SMD: 0.5,  
95% CI:  
-0.07-1.01 
P=0.09 78% 3 279 low 
Fatigue Incidence: 
any dose, any duration 
OR: 0.5,  
95% CI:  
0.13-1.61 
P=0.22 60% 4 375 very low 
Fatigue Incidence: 
any dose, ≤3-days duration 
OR: 0.2,  
95% CI:  
0.03-0.87 
P=0.03 0%c 2 219 Low 
Adverse Events 
Heartburn incidence: 
any dose, any duration 
OR: 1.9,  
95% CI:  
0.68-5.18 
P=0.22 0% 3 312 low 
Any gastrointestinal, flushing, rash-
related, or unspecified adverse 
event: 
any dose, any duration 
OR: 2.0,  
95% CI:  
1.39-2.99 
P=0.0003 0% 5 1458 moderate 
a. Subgroup analysis based on the four a priori groups of varied duration and dosage were not significantly 
different from each other. 
b. Sensitivity analysis did not identify a significant effect estimate 
c. Improved with sensitivity analysis 
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Figure 1. PRISMA flowchart of the search results and included papers in this systematic 
review with meta-analyses aiming to evaluate, in adult cancer patients receiving chemotherapy, 
the effects of ginger supplementation dose and duration on the incidence and severity of 
chemotherapy-induced nausea and vomiting and outcomes related to chemotherapy-induced 
nausea and vomiting (quality of life, fatigue). a Reference lists of included studies and previous 
systematic and narrative reviews were examined to identify additional studies not found in the 
systematic search strategy. 
Records identified through 
database searching: 
(n=203) 
Pubmed (n=25)  
Embase (n=78) 
Web of Science (n=67) 
CINAHL (n=9) 
Cochrane (n=24) 
 
Additional records identified 
through snowballinga 
(n=2) 
 
 Id
en
tif
ic
at
io
n 
Additional records identified 
in previous systematic review 
(n=8) 
 
 
 
Records screened title and 
abstract only  
(n=213) Sc
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in
g 
Number duplicates removed  
(n=89) 
Records excluded  
(n=87) 
Full-text papers assessed for 
eligibility  
(n=37) 
El
ig
ib
ili
ty
 Full-text papers excluded: 
(n=19) 
Ineligible population (n=2) 
Ineligible study design (n=3) 
Ineligible intervention (n=2) 
Abstract only (n=10) 
Unable to translate (n=2) 
 
 
 
 
In
cl
ud
ed
 
Papers included in qualitative 
synthesis  
(n =18) 
Papers included in meta-
analysis  
(n = 13) 
 28 
 
 
Figure 2. Risk of bias summary: Judgements from the review authors about bias in each paper 
included in this systematic review with meta-analyses aiming to evaluate, in adult cancer 
patients receiving chemotherapy, the effects of ginger supplementation dose and duration on 
the incidence and severity of chemotherapy-induced nausea and vomiting and outcomes related 
to chemotherapy-induced nausea and vomiting (quality of life, fatigue). 
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Figure 3. The likelihood of acute vomiting was reduced in adults undergoing chemotherapy 
by 60% with ginger supplementation of ≤1g/day for >3-days compared to control groups (OR: 
0.4, 95% CI: 0.17-0.81; P=0.01; n=3 studies; n=3 interventions; n=301 participants; I2=20%; 
GRADE level: moderate). Short Duration=≤3-days. Long Duration=>3-days. Low 
Dose=≤1g/day. High dose=>1g/day. OR=Odds ratio. CI=Confidence Interval. 
 
  
 30 
 
Figure 4. The likelihood of fatigue was reduced by 80% with ginger supplementation of any 
dose for <3-days duration compared to control groups (OR: 0.2, 95% CI: 0.03-0.87; P=0.03; 
n=1 studies; n=2 interventions; n=219 participants; I2=0%; GRADE level: low). Sensitivity 
analysis: studies which administered intervention for >3 days were excluded. OR=Odds ratio. 
CI=Confidence Interval. 
 
  
 31 
 
Figure 5. The likelihood of any gastrointestinal, flushing, rash-related or unspecified adverse 
event reasonably relatable to the intervention was increased in adults undergoing chemotherapy 
with ginger supplementation of any dose for any duration (OR: 2.0, 95% CI: 1.39-2.99; 
P=0.0003; n=3 studies; n=5 interventions; 1458 participants; I2=0%; GRADE level: moderate). 
OR=Odds ratio. CI=Confidence Interval. 
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Online Supplementary Material 1: Database Search Strategies 
 
Pubmed Database: 
(ginger[MeSH] OR ginger*[tiab] OR zingiber officinale*[tiab] OR “officinales, zingiber”[tiab]) AND 
(neoplasms[MeSH] OR “chemotherapy, adjuvant”[MeSH] OR “consolidation chemotherapy”[MeSH] 
OR “induction chemotherapy”[MeSH] OR “photochemotherapy”[MeSH] OR “maintenance 
chemotherapy”[MeSH] OR “chemotherapy, cancer, regional perfusion”[MeSH] OR “antineoplastic 
combined chemotherapy protocols”[MeSH] OR “electrochemotherapy”[MeSH] OR neoplas*[tiab] OR 
tumor*[tiab]  OR tumour*[tiab] OR malignanc*[tiab]  OR cancer*[tiab]  OR chemotherap*[tiab]  OR 
“antineoplastic combined chemotherapy regimens” [tiab]  OR antineoplastic chemotherapy 
protocol*[tiab] OR “chemotherapy protocol, antineoplastic” [tiab]  OR “protocol, antineoplastic 
chemotherapy” [tiab]  OR cancer chemotherapy protocol*[tiab] OR “protocol, cancer chemotherapy” 
[tiab]  OR “adjuvant chemotherapy” [tiab]  OR “consolidation chemotherapies” [tiab]  OR 
“chemotherapy, consolidation” [tiab]  OR “regional perfusion antineoplastic chemotherapy” [tiab]  OR 
“isolation perfusion cancer chemotherapy” [tiab]  OR “cancer chemotherapy, regional perfusion” [tiab]  
OR “perfusion cancer chemotherapy, regional” [tiab]  OR “regional perfusion cancer chemotherapy” 
[tiab]  OR electrochemotherapies OR “chemotherapy, induction” [tiab]  OR “maintenance 
chemotherapies”[tiab]  OR photochemotherapies[tiab]  AND (nausea[MeSH] OR vomiting [MeSH] OR 
emetics[MeSH] OR Antiemetics[MeSH] OR emesis[tiab] OR emetogenic[tiab] OR emetogenicity[tiab] 
OR nausea[tiab] OR nauseous[tiab] OR vomit*[tiab] OR emetic*[tiab] OR regurgit*[tiab]) OR 
“chemotherapy induced nausea and vomiting” [tiab] OR “chemotherapy‐induced nausea and vomiting” 
[tiab]  OR CINV[tiab] AND (Randomized controlled trial[pt] OR controlled clinical trial[pt] OR clinical 
study[pt] OR clinical trial[pt] OR comparative study[pt] OR randomized[tiab] OR randomised[tiab] OR 
placebo[tiab] OR OR randomly[tiab] OR trial[tiab] OR groups[tiab] OR “Single blind”[tiab] OR “Double 
blind”[tiab] OR intervention[tiab]) 
 
Web of Science Database: 
((ginger OR ginger* OR "zingiber officinale*" OR "officinales, zingiber") AND (neoplasms OR 
"chemotherapy, adjuvant" OR "consolidation chemotherapy" OR "induction chemotherapy" OR 
photochemotherapy OR "maintenance chemotherapy" OR "chemotherapy, cancer, regional 
perfusion" OR "antineoplastic combined chemotherapy protocols" OR electrochemotherapy OR 
neoplas* OR tumor* OR tumour* OR malignanc* OR cancer* OR chemotherap* OR "antineoplastic 
combined chemotherapy regimens" OR "antineoplastic chemotherapy protocol*" OR "chemotherapy 
protocol, antineoplastic" OR "protocol, antineoplastic chemotherapy" OR "cancer chemotherapy 
protocol*" OR "protocol, cancer chemotherapy" OR "adjuvant chemotherapy" OR "consolidation 
chemotherapies" OR "chemotherapy, consolidation" OR "regional perfusion antineoplastic 
chemotherapy" OR "isolation perfusion cancer chemotherapy" OR "cancer chemotherapy, regional 
perfusion" OR "perfusion cancer chemotherapy, regional" OR "regional perfusion cancer 
chemotherapy" OR electrochemotherapies OR "chemotherapy, induction" OR "maintenance 
chemotherapies" OR photochemotherapies OR "chemotherapy induced nausea and vomiting" OR 
"chemotherapy‐induced nausea and vomiting" OR CINV) AND (nausea OR vomiting OR emetics OR 
Antiemetics OR emesis OR emetogenic OR emetogenicity OR nausea OR nauseous OR vomit* OR 
 33 
emetic* OR regurgit*) AND ("Randomized controlled trial" OR "controlled clinical trial" OR "clinical 
study" OR "clinical trial" OR "comparative study" OR randomized OR randomised OR placebo OR 
randomly OR trial OR groups OR "Single blind" OR "Double blind" OR intervention)) 
 
Embase Database: 
('ginger'/exp OR ginger*:ti,ab OR 'zingiber officinale*':ti,ab OR 'officinales, zingiber':ti,ab) AND 
('neoplasms'/exp OR 'chemotherapy, adjuvant'/exp OR 'consolidation chemotherapy'/exp OR 
'induction chemotherapy'/exp OR 'photochemotherapy'/exp OR 'maintenance chemotherapy'/exp 
OR 'chemotherapy, cancer, regional perfusion'/exp OR 'antineoplastic combined chemotherapy 
protocols'/exp OR 'electrochemotherapy'/exp OR neoplas*:ti,ab OR tumor*:ti,ab OR tumour*:ti,ab 
OR malignanc*:ti,ab OR cancer*:ti,ab OR chemotherap*:ti,ab OR 'antineoplastic combined 
chemotherapy regimens':ti,ab OR 'antineoplastic chemotherapy protocol*':ti,ab OR 'chemotherapy 
protocol, antineoplastic':ti,ab OR 'protocol, antineoplastic chemotherapy':ti,ab OR 'cancer 
chemotherapy protocol*':ti,ab OR 'protocol, cancer chemotherapy':ti,ab OR 'adjuvant 
chemotherapy':ti,ab OR 'consolidation chemotherapies':ti,ab OR 'chemotherapy, consolidation':ti,ab 
OR 'regional perfusion antineoplastic chemotherapy':ti,ab OR 'isolation perfusion cancer 
chemotherapy':ti,ab OR 'cancer chemotherapy, regional perfusion':ti,ab OR 'perfusion cancer 
chemotherapy, regional':ti,ab OR 'regional perfusion cancer chemotherapy':ti,ab OR 
electrochemotherapies OR 'chemotherapy, induction':ti,ab OR 'maintenance chemotherapies':ti,ab 
OR photochemotherapies:ti,ab OR 'chemotherapy induced nausea and vomiting':ti,ab OR 
'chemotherapy‐induced nausea and vomiting':ti,ab OR cinv:ti,ab) AND ('nausea'/exp OR 
'vomiting'/exp OR 'emetics'/exp OR 'antiemetics'/exp OR emesis:ti,ab OR emetogenic:ti,ab OR 
emetogenicity:ti,ab OR nausea:ti,ab OR nauseous:ti,ab OR vomit*:ti,ab OR emetic*:ti,ab OR 
regurgit*:ti,ab) AND ('randomized controlled trial':it OR 'controlled clinical trial':it OR 'clinical study':it 
OR 'clinical trial':it OR 'comparative study':it OR randomized:ti,ab OR randomised:ti,ab OR 
placebo:ti,ab OR randomly:ti,ab OR trial:ti,ab OR groups:ti,ab OR 'single blind':ti,ab OR 'double 
blind':ti,ab OR intervention:ti,ab) 
 
CINAHL Database: 
((((MH "ginger+") OR TI ginger* OR AB ginger* OR TI  
"zingiber officinale*" OR AB "zingiber officinale*" OR TI "officinales,  
zingiber" OR AB "officinales, zingiber") AND ((MH "neoplasms+") OR (MH  
"chemotherapy, adjuvant+") OR (MH "consolidation chemotherapy+") OR (MH  
"induction chemotherapy+") OR (MH "photochemotherapy+") OR (MH "maintenance 
chemotherapy+") OR (MH "chemotherapy, cancer, regional perfusion+") OR (MH "antineoplastic 
combined chemotherapy protocols+") OR (MH  
"electrochemotherapy+") OR TI neoplas* OR AB neoplas* OR TI tumor* OR AB  
tumor* OR TI tumour* OR AB tumour* OR TI malignanc* OR AB malignanc* OR TI cancer* OR AB 
cancer* OR TI chemotherap* OR AB chemotherap* OR TI  
"antineoplastic combined chemotherapy regimens" OR AB "antineoplastic  
combined chemotherapy regimens" OR TI "antineoplastic chemotherapy protocol*"  
OR AB "antineoplastic chemotherapy protocol*" OR TI "chemotherapy protocol,  
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antineoplastic" OR AB "chemotherapy protocol, antineoplastic" OR TI  
"protocol, antineoplastic chemotherapy" OR AB "protocol, antineoplastic  
chemotherapy" OR TI "cancer chemotherapy protocol*" OR AB "cancer  
chemotherapy protocol*" OR TI "protocol, cancer chemotherapy" OR AB  
"protocol, cancer chemotherapy" OR TI "adjuvant chemotherapy" OR AB "adjuvant  
chemotherapy" OR TI "consolidation chemotherapies" OR AB "consolidation  
chemotherapies" OR TI "chemotherapy, consolidation" OR AB "chemotherapy,  
consolidation" OR TI "regional perfusion antineoplastic chemotherapy" OR AB  
"regional perfusion antineoplastic chemotherapy" OR TI "isolation perfusion  
cancer chemotherapy" OR AB "isolation perfusion cancer chemotherapy" OR TI  
"cancer chemotherapy, regional perfusion" OR AB "cancer chemotherapy,  
regional perfusion" OR TI "perfusion cancer chemotherapy, regional" OR AB  
"perfusion cancer chemotherapy, regional" OR TI "regional perfusion cancer  
chemotherapy" OR AB "regional perfusion cancer chemotherapy" OR  
electrochemotherapies OR TI "chemotherapy, induction" OR AB "chemotherapy,  
induction" OR TI "maintenance chemotherapies" OR AB "maintenance  
chemotherapies" OR TI photochemotherapies OR AB photochemotherapies OR TI  
"chemotherapy induced nausea and vomiting" OR AB "chemotherapy induced nausea  
and vomiting" OR TI "chemotherapy‐induced nausea and vomiting" OR AB  
"chemotherapy‐induced nausea and vomiting" OR TI CINV OR AB CINV AND ((MH "nausea+") OR (MH 
"vomiting+") OR (MH "emetics+") OR (MH "Antiemetics+") OR TI emesis OR AB emesis OR TI 
emetogenic OR AB emetogenic OR TI emetogenicity OR AB emetogenicity OR TI nausea OR AB nausea 
OR TI nauseous OR AB nauseous OR TI vomit* OR AB vomit* OR TI emetic* OR AB emetic* OR TI 
regurgit* OR AB regurgit*))) 
 
Cochrane Library Database: 
#1 MeSH descriptor: [Ginger] explode all trees 
#2 MeSH descriptor: [Neoplasms] explode all trees 
#3 (ginger*:ti,ab or "zingiber officinale*":ti,ab or "officinales, zingiber":ti,ab)  
#4 #1 or #3  
#5 (neoplas*:ti,ab or tumor*:ti,ab or tumour*:ti,ab or malignanc*:ti,ab or cancer*:ti,ab or 
chemotherap*:ti,ab or "antineoplastic combined chemotherapy regimens":ti,ab or 
"antineoplastic chemotherapy protocol*":ti,ab or "chemotherapy protocol, 
antineoplastic":ti,ab or "protocol, antineoplastic chemotherapy":ti,ab or "cancer 
chemotherapy protocol*":ti,ab or "protocol, cancer chemotherapy":ti,ab or "adjuvant 
chemotherapy":ti,ab or "consolidation chemotherapies":ti,ab or "chemotherapy, 
consolidation":ti,ab or "regional perfusion antineoplastic chemotherapy":ti,ab or "isolation 
perfusion cancer chemotherapy":ti,ab or "cancer chemotherapy, regional perfusion":ti,ab or 
"perfusion cancer chemotherapy, regional":ti,ab or "regional perfusion cancer 
chemotherapy":ti,ab or electrochemotherapies or "chemotherapy, induction":ti,ab or 
"maintenance chemotherapies":ti,ab or photochemotherapies:ti,ab or "chemotherapy 
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induced nausea and vomiting":ti,ab or "chemotherapy‐induced nausea and vomiting":ti,ab or 
CINV:ti,ab)  
#6 MeSH descriptor: [Chemotherapy, Adjuvant] explode all trees 
#7 MeSH descriptor: [Consolidation Chemotherapy] explode all trees 
#8 MeSH descriptor: [Induction Chemotherapy] explode all trees 
#9 MeSH descriptor: [Photochemotherapy] explode all trees 
#10 MeSH descriptor: [Maintenance Chemotherapy] explode all trees 
#11 MeSH descriptor: [Chemotherapy, Cancer, Regional Perfusion] explode all trees 
#12 MeSH descriptor: [Antineoplastic Combined Chemotherapy Protocols] explode all trees 
#13 MeSH descriptor: [Electrochemotherapy] explode all trees 
#14 #2 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13  
#15 MeSH descriptor: [Nausea] explode all trees 
#16 MeSH descriptor: [Vomiting] explode all trees 
#17 MeSH descriptor: [Emetics] explode all trees 
#18 MeSH descriptor: [Antiemetics] explode all trees 
#19 (emesis:ti,ab or emetogenic:ti,ab or emetogenicity:ti,ab or nausea:ti,ab or nauseous:ti,ab or 
vomit*:ti,ab or emetic*:ti,ab or regurgit*:ti,ab)  
#20 #15 or #16 or #17 or #18 or #19  
#21 ("Randomized controlled trial":pt or "controlled clinical trial":pt or "clinical study":pt or 
"clinical trial":pt or "comparative study":pt or randomized:ti,ab or randomised:ti,ab or 
placebo:ti,ab or randomly:ti,ab or trial:ti,ab or groups:ti,ab or "Single blind":ti,ab or "Double 
blind":ti,ab or intervention:ti,ab)  
#22 #4 and #14 and #20 and #21 
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Online Supplementary Material 2: Cochrane Risk of Bias Assessment  
 
Table 1. Cochrane Risk of Bias assessment with justifications for included studies located in the updated search (n=13), examining the effect of ginger 
supplementation on chemotherapy-induced nausea and vomiting incidence and related outcomes. 
  Study Random sequence 
generation (selection 
bias) 
Allocation 
concealment 
(selection bias) 
Blinding of 
participants and 
personnel 
(performance bias) 
Blinding of outcome 
assessment (detection 
bias) 
Incomplete 
outcome data 
(attrition bias) 
Selective 
reporting 
(reporting bias) 
Other bias 
Rating 
Alparslan 2012 
 Risk of bias: Unclear  Risk of bias: Unclear  Risk of bias: High  Risk of bias: High  Risk of bias: 
Unclear 
Low Low 
Evidence No mention of 
description of 
randomisation or how 
participants were 
allocated to each group. 
However, no difference 
between baseline 
characteristics (P>0.05). 
No description of 
how allocation was 
conducted. 
No attempt at blinding 
made (Intervention 
group received ginger 
tablet and no anti-
emetics, control group 
received anti-emetics 
and no ginger) 
therefore outcomes 
likely to be influenced 
(more so nausea than 
vomiting incidence) 
and effect of 
intervention may have 
been overestimated.  
Vomiting incidence 
objective, however, 
nausea subjective and 
assessment completed by 
participants who were not 
blinded to the 
intervention or outcome, 
therefore likely to effect 
outcome and effect of 
intervention may have 
been overestimated. 
No raw data 
provided (tables 
missing from paper) 
therefore no 
indication of 
attrition. 
No study protocol 
identified, 
however, all pre-
specified 
expected 
outcomes 
included in 
publication as 
intended.  
The study appears 
to be free of other 
sources of bias. 
Rating 
Arslan 2015 
 Risk of bias: High  Risk of bias: High  Risk of bias: High  Risk of bias: High  Risk of bias: 
Unclear 
 Risk of bias: 
Low 
 Risk of bias: Low 
Evidence "No significant 
differences were seen 
between the intervention 
and control group 
(p>0.05)" however, the 
raw data was not 
reported and the patients 
were "randomized 
sequentially to the two 
groups (control and 
intervention); that is, the 
first patient was 
assigned to the control 
group and the next one 
to the intervention 
group." I.e. alternate 
allocation / quasi-
randomisation used 
The patients were 
randomised 
sequentially to the 
two groups (control 
and intervention); 
that is, the first 
patient was assigned 
to the control group 
and the next one to 
the intervention 
group, therefore 
allocation 
concealment 
inadequate. 
No attempt at blinding 
made (Intervention 
group received ginger 
powder, control group 
received nothing) 
therefore outcomes 
likely to be influenced 
(more so nausea than 
vomiting incidence) 
and effect of 
intervention may have 
been overestimated.  
"The patient diary was 
given to the patients in 
the intervention and 
control groups, and they 
were asked to complete 
the diary four times a day 
at home". Vomitting 
incidence objective, 
however, nausea 
subjective  and 
assessment completed by 
participants who were not 
blinded to the 
intervention,  therefore 
likely to effect outcome 
and effect of intervention 
may have been 
overestimated. 
No mention of 
attrition or sample 
size per group. 
No study protocol 
identified, 
however, all pre-
specified 
expected 
outcomes 
included in 
publication as 
intended. 
The study appears 
to be free of other 
sources of bias. 
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which is predictable and 
likely to create 
differences between the 
groups. 
Rating  
Bossi 2017 
 Risk of bias: Low  Risk of bias: Unclear Risk of bias: Low  Risk of bias: Low Risk of bias: 
Unclear 
 Risk of bias: 
Low 
 Risk of bias: High 
Evidence "patients were randomly 
assigned, according to a 
pre-defined computer 
generated list (RALLOC 
of STATA)." Baseline 
characteristics not 
statistically analysed, 
however appear similar 
suggesting 
randomisation executed 
successfully. 
No description of 
how allocation was 
conducted. 
"double-blind, 
placebo-controlled 
trial". Either ginger 
extract 40mg/capsule 
(provided by Helsinn) 
or matching placebo. 
"All patients received a 
patient diary" with 
questionnaires. As 
patients blinded to 
outcomes, unlikely to 
have influenced results.  
"39% participants 
withdrew 
prematurely" 
however "dropout 
rate did not differ 
between treatment 
groups (ginger: 
42.4%; placebo 
34.9%; P=0.22)." 
Intention to treat 
used but n=251 
before attrition, 
n=244 included in 
results. 
Study protocol 
identified and all 
pre-specified 
expected 
outcomes 
included in 
publication as 
intended.  
Some authors are 
paid or employed 
by funding 
company. 
Rating 
Danwilai 2017  
 Risk of bias: Low  Risk of bias: Unclear  Risk of bias: Low  Risk of bias: Low  Risk of bias: Low  Risk of bias: 
Low 
 Risk of bias: Low 
Evidence "participants were 
randomly assigned into 
two groups using a 
block of four 
randomization 
techniques. The study 
coordinator generated a 
randomization list to 
assign participants to 
receive either ginger 
extract (stan- dardized 
6-gingerol) or placebo." 
Randomisation thought 
to be successfully 
executed given that 
there was "no difference 
No description of 
how allocation was 
conducted. 
"double-blind, placebo 
controlled trial". "The 
standardized 6-
gingerol and placebo 
capsules were placed 
into packages of 
similar color and 
size." 
"The investigators and 
participants were blinded 
to the randomization list 
and treatment 
assignments." 
14% attrition. 6 
withdrawn from 
ginger group, one 
from placebo, 
however, no 
statistical analysis 
done between 
groups however 
likely to be 
insignificant and 
not effect results.  
None detected The study appears 
to be free of other 
sources of bias. 
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between baseline 
characteristics 
(P>0.05)." 
Rating 
Konmun 2017 
Risk of bias: Low  Risk of bias: Unclear  Risk of bias: Low  Risk of bias: Low Risk of bias: Low  Risk of bias: 
Low 
Risk of bias: Low 
Evidence Particpants were 
"randomly assigned... 
utilizing a block four 
method for 
randomization." 
Randomisation thought 
to be successfully 
executed given that 
there were no 
differences between 
baseline characteristics 
reported. 
No description of 
how allocation was 
conducted. 
"double-blind, 
placebo-controlled 
trial" "placebo 
capsules … match the 
weight of the 6-
gingerol capsules" 
"patients were required to 
complete a daily diary … 
The diary included 
number of vomiting 
episodes, nausea score, 
appetite score, quality of 
life, use of rescue anti-
emetic, and 
hospitalization." As 
patients blinded to 
outcomes well, unlikely 
to have influenced results. 
14% attrition. 
Withdrawal 
numbers and 
reasons similar 
between groups. 
Atrrition well 
documented. 
No study protocol 
identified, 
however, all pre-
specified 
expected 
outcomes 
included in 
publication as 
intended. 
The study appears 
to be free of other 
sources of bias. 
Rating 
Li 2018 
 Risk of bias: Unclear Risk of bias: Unclear  Risk of bias: Low  Risk of bias: Low  Risk of bias: Low Risk of bias: Low  Risk of bias: Low 
Evidence  No mention of 
description of 
randomisation or how 
participants were 
allocated to each group. 
However, no difference 
between baseline 
characteristics (P>0.05). 
No description of 
how allocation was 
conducted. 
"double-blind, 
placebo-controlled 
clini- cal trial" "The 
placebo capsules were 
physically identical to 
the ginger capsules" 
Both participants and 
researchers blinded to 
outcomes. 
4% attrition. 
Reasons for this and 
numbers per group 
given. No intention 
to treat used 
however, 6 drop 
outs unlikely to 
influence results.  
No study protocol 
identified, 
however, all pre-
specified 
expected 
outcomes 
included in 
publication as 
intended. 
The study appears 
to be free of other 
sources of bias. 
Rating 
Marx 2017 
 Risk of bias: Low Risk of bias: Low  Risk of bias: Low  Risk of bias: Low  Risk of bias: Low Risk of bias: 
Unclear 
 Risk of bias: Low 
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Evidence  "randomly allocated… 
by an independent 
company using a 
computer-generated 
sequence." Baseline 
characteristics not 
statistically analysed, 
however appear similar 
suggesting 
randomisation executed 
successfully. 
"Eligible patients 
were randomly 
allocated to ginger or 
placebo capsules by 
an independent 
company using a 
computer-generated 
sequence."  
"All staff members 
involved in 
recruitment and 
outcome assessment 
were blinded to the 
results of 
randomization." 
Placebo capsules same 
appearance and 
weight. Double-
enapsulated. 
Participants self-
completed questionnaires 
and blinded to outcomes.  
Intention to treat 
used (34/51 
completed all 
cycles, however, 51 
included in 
analysis). Attrition 
well documented. 
Results reported 
differ from those 
pre-specified in 
study protocol, 
however, 
explanations 
provided in 
publication. 
The study appears 
to be free of other 
sources of bias. 
Rating 
Montazeri 2013 
 Risk of bias: Low  Risk of bias: Unclear  Risk of bias: Low  Risk of bias: Low  Risk of bias: High  Risk of bias: 
Unclear 
 Risk of bias: Low 
Evidence "This study is a 
randomized, 
prospective, cross-over 
double - blinded clinical 
trial," "This study was 
doing on the basis of the 
block randomization 
with the four block 
method."  
No description of 
how allocation was 
conducted. 
"Double-blind, 
placebo-controlled 
trial" "The shape, 
colour and fragrance 
of this powder were 
similar to ginger and 
both of them were 
provided by the same 
company." 
Both participants and 
researchers blinded to 
outcomes. 
32% attrition. 13/44 
unable to complete 
second cycle of 
study.  Reasons for 
this given but 
dropouts per group 
not given. Unclear 
whether intention to 
treat used.  
 Unclear whether 
outcome data 
missing from 
analysis and 
whether this 
could have effect 
on results. 
The study appears 
to be free of other 
sources of bias. 
Rating 
Muthia 2013 
 Risk of bias: Unclear  Risk of bias: Unclear  Risk of bias: High  Risk of bias: High  Risk of bias: 
Unclear 
 Risk of bias: 
Low 
 Risk of bias: Low 
Evidence No mention or 
description of 
randomisation or how 
participants were 
allocated to each group. 
No statistical analysis of 
baseline characteristics 
to determine whether 
sequence generation free 
from bias.   
No description of 
how allocation was 
conducted. 
No attempt at blinding 
made (Intervention 
group received ginger 
drink, control group 
did not) therefore 
outcome of vomiting 
and mainly nausea 
likely to be influenced 
and effect of 
intervention may have 
been overestimated.  
Rhodes Index for Nausea, 
Vomiting and Retching 
subjective and seeing as 
participants and 
researchers not blinded to 
treatment and outcomes, 
likely to influence results 
and effect of intervention 
may have been 
overestimated.  
No mention of 
attrition or sample 
size per group. 
No study protocol 
identified, 
however, all pre-
specified 
expected 
outcomes 
included in 
publication as 
intended. 
The study appears 
to be free of other 
sources of bias. 
Rating Sanaati 2016  Risk of bias: Low  Risk of bias: Low  Risk of bias: High  Risk of bias: High  Risk of bias: High  Risk of bias: Low 
 Risk of bias: Low 
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Evidence "randomly 
allocated …using the 20 
block random tables." 
Randomisation thought 
to be successfully 
executed given that 
there was no difference 
between baseline 
characteristics reported 
(P>0.05). 
Coding and blinding 
of the two groups 
were performed 
privately by the 
pharmacologist 
consultant. 
Control group given 
no intervention, 
treatment groups 
aware receiving 
intervention and only 
blinded to whether 
receiving ginger or 
chamomile capsules. 
Outcome likely to be 
influenced and effect 
of intervention may 
have been 
overestimated.  
"A self-made, two-part 
self- reporting instrument 
was used to measure the 
frequency and severity of 
nausea and vomiting". 
Frequency of vomitting 
objective, however, 
nausea frequency/severity 
and vomitting severity 
subjective outcomes 
likely to be influenced by 
the fact that participants 
were not blinded to 
receiving treatment/not 
and effect of intervention 
may have been 
overestimated.  
30% attrition. 13 
out of 43 
interrupted their 
participation 
(excluding 
chamomile group). 
Reasons given, 
however, no 
differentiation 
between groups and 
number of drop outs 
per group not given. 
No intention to treat 
used. 
Study Protocol 
pre-registered and 
all pre-specified 
expected 
outcomes 
included in 
publication as 
intended. 
The study appears 
to be free of other 
sources of bias. 
Rating 
Shokri 2017 
 Risk of bias: Unclear  Risk of bias: Unclear  Risk of bias: Low  Risk of bias: Low  Risk of bias: 
Unclear 
 Risk of bias: 
Low 
 Risk of bias: Low 
Evidence "The patients were 
divided into 2 random 
groups. They were then 
divided into 2 
homogeneous groups 
(using Randlist) based 
on their satisfaction to 
receive ginger in terms 
of the history of lack of 
neoplastic diseases in 
women, history of lack 
of chemotherapy and 
stage of cancer." 
Unclear whether those 
that were happy to 
receive and comply with 
ginger intervention more 
likely to be allocated 
that intervention. 
However, no statistically 
signficant differences 
between other baseline 
characteristcs . 
No description of 
how allocation was 
conducted. 
"Examiners and the 
patients were unaware 
of the coding and the 
real grouping was only 
specified after 
statistical analysis." 
Placebo used. 
No indication how nausea 
and vomitting outcome 
assessed. As participants 
and researchers blinded to 
intervention, unlikely to 
effect outcomes.  
No mention of 
attrition or sample 
size per group. 
Study Protocol 
pre-registered and 
all pre-specified 
expected 
outcomes 
included in 
publication as 
intended. 
The study appears 
to be free of other 
sources of bias. 
Rating Thamlikitkul 2017  Risk of bias: Low  Risk of bias: Unclear  Risk of bias: Low  Risk of bias: Low  Risk of bias: Low  Risk of bias: Low 
 Risk of bias: Low 
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Evidence "subjects were randomly 
assigned in a 1:1 ratio 
from the stratified 
randomization table." 
Baseline characteristics 
not reported per group 
due to cross over design.  
No description of 
how allocation was 
conducted. 
"The placebo and 
ginger capsules and 
their packaging were 
physically identical. 
The investigators and 
subjects were blinded 
to the randomization 
list and treatment 
assignments." 
Participants filled out 
questionnaires and were 
blinded to outcome 
measures and 
intervention, therefore 
unlikely to effect 
outcomes. 
No attrition, all 
participants 
completed the 
study. 
Study Protocol 
pre-registered and 
all pre-specified 
expected 
outcomes 
included in 
publication as 
intended. 
The study appears 
to be free of other 
sources of bias. 
Rating 
Yekta 2012 
 Risk of bias: Low  Risk of bias: Unclear  Risk of bias: Low  Risk of bias: Low  Risk of bias: Low  Risk of bias: 
Low 
 Risk of bias: Low 
Evidence "The patients were 
randomly 
allocated…using the 20 
block random tables." 
No statistically 
signficant differences 
between baseline 
characteristcs suggesting 
randomisation executed 
successfully. 
No description of 
how allocation was 
conducted. 
"placebo capsules ... 
exactly the same size, 
shape, color, taste, and 
dosage as Zintoma 
capsules." "Coding 
and blinding of the 2 
groups were 
performed privately 
by the pharmacologist 
consultant, and all of 
the samples, data 
analyzers, and all 
participants too, were 
unaware of the real 
content of the capsule" 
Participants used self-
reporting instruments to 
document outcomes and 
seeing as participants 
were blinded to 
intervention, unlikely to 
have effected results. 
Outcome of vomiting 
incidence objective rather 
than subjective. 
18% attrition 
relatively low, 
reasons given for 
this along with 
numbers per group. 
No intention to treat 
used however, 18 
drop outs unlikely 
to influence results.  
Study Protocol 
pre-registered and 
all pre-specified 
expected 
outcomes 
included in 
publication as 
intended. 
The study appears 
to be free of other 
sources of bias. 
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Table 2. Cochrane Risk of Bias assessment with justifications for included studies located in the researchers’ previous systematic review (n=5), examining 
the effect of ginger supplementation on chemotherapy-induced nausea and vomiting incidence and related outcomes. 
 
Rating 
Fahimi 2011 
 Risk of bias: Unclear  Risk of bias: Unclear  Risk of bias: Low  Risk of bias: Low  Risk of bias: 
Unclear 
 Risk of bias: Low  Risk of bias: 
Low 
Evidence Participants randomised, 
however, specific 
information on how this 
was carried out not given. 
Baseline characteristics 
not reported per group 
due to cross over design.  
"The monitoring 
investigator dispensed 
either active drug or 
placebo according to 
the randomization 
table." No information 
given as to  whether or 
not this was concealed. 
Placebo capsules were 
"identical". Participants 
were blinded to the 
intervention received also.  
Questionnaires given to 
particpant to complete, 
and seeing as patients 
blinded to intervention, 
unlikely to have effected 
results. 
28% attrrition. 
36/50 completed the 
study. Reasons 
given, however, did 
not specify which 
intervention they 
were undergoing 
when they 
discontinued 
therefore unsure 
whether relatable to 
the ginger 
intervention. 
Unclear whether 
intention to treat 
used. 
No study protocol 
identified, 
however, all pre-
specified expected 
outcomes 
included in 
publication as 
intended. 
The study appears 
to be free of other 
sources of bias. 
Rating 
Manusirivithaya 
2004 
 Risk of bias: Low  Risk of bias: Unclear  Risk of bias: Low  Risk of bias: Low  Risk of bias: Low   Risk of bias: Low  Risk of bias: 
Low 
Evidence Participants were 
"randomly assigned by 
block of four." Baseline 
characteristics not 
reported per group due to 
cross over design.  
No description of how 
allocation was 
conducted. 
Participants and research 
team blinded to 
intervention. "All of these 
capsules were identical in 
appearance, contour, size, 
and color." 
Scale of nausea severity 
self-reported. Both 
participants and 
researchers blinded to 
outcomes. 
10% attrition. 
Reasons not given, 
however numbers 
per regimen given 
and same for each 
group. Intention to 
treat not used (48 
recruited, 43 only 
included in data 
analysis), however, 
not likely to effect 
results. 
No study protocol 
identified, 
however, all pre-
specified expected 
outcomes 
included in 
publication as 
intended. 
The study appears 
to be free of other 
sources of bias. 
Rating  Panahi 2012  Risk of bias: High  Risk of bias: High  Risk of bias: High  Risk of bias: High  Risk of bias: Low   Risk of bias: Low  Risk of bias: Low 
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Evidence "The participants of this 
open-label trial were 
individually and 
alternatively allocated to 
ginger or control group 
with the first allocation 
being chosen randomly. 
At the beginning of study 
and before patient 
recruitment, blank 
questionnaires were 
numbered and 
alternatively coded as 
ginger or control. The 
first code was chosen 
randomly (by lottery)." 
The patients were 
randomised 
sequentially to the two 
groups (control and 
intervention); that is, 
the first patient was 
assigned to the control 
group and the next one 
to the intervention 
group, therefore 
allocation concealment 
inadequate. 
No placebo used therefore 
participants and 
researchers not blinded to 
the intervention. Therefore 
outcomes likely to be 
influenced and effect of 
intervention may have 
been overestimated.  
Questionnaires were self 
reported. However, 
participants knew which 
intervention they 
received therefore likely 
to influence results and 
overestimate effect of 
intervention.  
22% attrition 
(22/100 didn't 
complete the study). 
Reasons given and 
numbers per group 
and dropout rate not 
statistically 
significantly 
different between 
the groups. Intention 
to treat appears not 
to have been, 
however, 22 drop 
outs unlikely to 
affect results. 
No study protocol 
identified, 
however, all pre-
specified expected 
outcomes 
included in 
publication as 
intended. 
The study appears 
to be free of other 
sources of bias. 
Rating 
Ryan 2012 
 Risk of bias: Low  Risk of bias: Unclear  Risk of bias: Low  Risk of bias:   Risk of bias: Low  Risk of bias: Low  Risk of bias: 
Low 
Evidence "Randomization was 
stratified by CCOP site. 
Within each site, a 
computer-generated 
random number table 
with block size eight was 
used to randomly assign 
patients to one of four 
treatment arms." No 
statistically signficant 
differences between 
baseline characteristcs 
suggesting randomisation 
executed successfully. 
No description of how 
allocation was 
conducted. 
Placebo capsules made to 
be identical in weight and 
appearance, and double 
encapsulated.  
Questionnaires given to 
participant to complete, 
and seeing as patients 
blinded to intervention, 
unlikely to have effected 
results. 
23% attrition. Some 
intention to treat 
used where possible. 
Numbers per group 
and reasons given. 
Study Protocol 
pre-registered and 
all pre-specified 
expected 
outcomes 
included in 
publication as 
intended. 
The study appears 
to be free of other 
sources of bias. 
Rating 
Zick 2009 
 Risk of bias: Low  Risk of bias: Low  Risk of bias: Low  Risk of bias: Low  Risk of bias: Low  Risk of bias: Low  Risk of bias: 
Low 
Evidence  "The randomization code 
blocked by research site 
was computer-generated 
by the study 
biostatistician." Baseline 
characteristics not 
statistically analysed, 
however appear similar 
suggesting randomisation 
executed successfully. 
" All study participants 
as well as all study 
personnel who 
assessed outcomes, 
worked with study 
data, or administered 
tests or questionnaires 
were unaware of the 
randomization list or 
treatment assignment. 
"  
"All study participants as 
well as all study personnel 
who assessed outcomes, 
worked with study data, or 
adminis- tered tests or 
questionnaires were 
unaware of the 
randomization list or 
treatment assignment." 
Placebo capsules made to 
mimic ginger. 
 As participants and 
researchers blinded to 
intervention, unlikely to 
effect outcomes.  
20% attrition 
(33/162). Intention 
to treat used. 
Reasons per group 
for drop outs given, 
numbers and 
reasons don't appear 
drastically different 
between groups.  
No study protocol 
identified, 
however, all pre-
specified expected 
outcomes 
included in 
publication as 
intended. 
The study appears 
to be free of other 
sources of bias. 
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Online Supplementary Material 3: Characteristics of Included Studies 
 
Table 1. Included studies located in the updated search strategy (n=13), examining the effect of ginger supplementation on chemotherapy-induced nausea 
and vomiting incidence and chemotherapy-related outcomes.  
Citation Study Design & Setting  Population  CTx Protocol 
Adjuvant 
Therapies 
Intervention 
Group/s (IG)  
Comparator 
Group/s 
(CG) 
Results  
Alparslan 2012 
(24) 
Design: Non-
RCT  
Country: 
Turkey 
Study 
Duration 
Dates: March 
2011 to July 
2011 
 
N: 45  
Attrition: 0% 
Females: n=15  
Age: 60% were 
46-80 years 
Cancer type: 
Hematological 
(64% 
leukaemia) 
History of 
CINV: Not 
specified 
None specified. 
51% were on 
their first course 
of treatment 
None 
specified 
n: 15 
Type: ginger 
tablet 
Dose: 1.6g/d 
(2x0.4g BD) 
Duration: 
Throughout 
course of 
treatment 
(length 
unspecified) 
n: 30 
Type: IV anti-
emetic (3mg 
setron)   
 
CINVa 
Incidence (time point not specified): 
- IG n=0/15; CG n=23/30; P<0.05 between groups 
Mortality 
Not reported 
 
 
Arslan 2015 
(25) 
 
Design: RCT 
Country: 
Turkey 
Dates: Not 
specified 
N: 60 
Attrition: 0% 
Female: n=60 
Age: mean 48.5 
years 
Cancer:  Breast 
cancer (stage II 
or III) with 
previous 
surgical 
treatment 
History of 
CINV: Yes, 
established in 
previous 
Cycles. No 
difference 
between groups 
 
Drugs: 
Anthracycline, 
cyclophosphami
de, doxorubicin 
and 5-
fluorouracil  
Emetogenicity: 
Not specified 
Single or multi 
day:  
Single 
Commencing 
Cycle: ≥2nd 
Cycle 
Cycle length: 
Not specified 
 
5-HT3 
receptor 
antagonist 
(palonosetr
on), 
dexamethas
one, an 
antihistami
ne 
(ranitidine( 
(Day 1); 
PO 
aprepitant 
(Days 1-3) 
n: 30 
Type: 0.5g 
powdered 
ginger sachet 
mixed with 
yoghurt 
Dose: 1g/d 
(0.5g BD) 
Duration: 3 
days; 1st dose 
30 mins 
before CTx; 
for 2 Cycles 
 
n: 30 
Type: 
Standard care 
(no ginger) 
CIN 
Severity (mean score (SD); specially formulated tool; score ranges 0-10; higher score 
indicates more severe CIN): 
- Day 1 (acute severity): IG 0.8 (0.9); CG 1.2 (1.1); P=0.15 between groups 
- Day 2: IG 3.8 (1.9); CG 6.3 (1.9); P<0.001 between groups 
- Day 3: IG 3.8 (1.8); CG 6.5 (1.8); P=0.001 between groups 
- Day 4: IG 3.7 (1.9); CG 6.3 (1.8); P=0.001 between groups 
- Day 5: IG 2.8 (1.7); CG 5.4 (2.3); P=0.001 between groups 
- Overall Severity (mean of Day 1-5 scores):b IG 2.98 (1.64); CG 5.14 (1.78) 
- Delayed Severity (mean of Day 2-5 scores):b IG 3.53 (1.83); CG 6.13 (1.95) 
- Delayed Nausea (time point not specified): IG 3.6 (1.8); CG 6.1 (1.7); P<0.001 between 
groups 
- Acute Nausea (time point not specified): IG 1.6 (1.1); CG 3.9 (1.6); P<0.001 between 
groups 
- Before Intervention (time point not specified): IG 5.3 (1.0); CG 5.2 (1.5); P=0.9 between 
groups 
- After Intervention (time point unclear): IG 3 (1.5); CG 5.1 (1.5); P<0.001 between groups 
CIV 
Incidence (mean number of episodes (SD); measured 4 times each day): 
- Day 1: IG 0 (0.1); CG 0.1 (0.2); P=0.21 between groups 
- Day 2: IG 0 (0.1); CG 0.3 (0.6); P=0.01 between groups 
- Day 3: IG 0 (0.1); CG 0.2 (0.4); P=0.01 between groups 
- Day 4: IG 0 (0.1); CG 0.1 (0.4); P=0.07 between groups 
- Day 5: IG 0 (0.0); CG 0.2 (0.4); P=0.04 between groups 
- After Intervention (time point unclear): IG 0 (0); CG 0.2 (0.3); P=0.011 between groups 
Mortality 
Not reported 
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Bossi 2017 
(39) 
 
Design: 
Double-blind 
placebo- 
controlled 
randomised 
trial 
Country: Italy 
Data 
Collection 
Dates: June 
2013 to April 
2015 
 
N: 251 
Attrition: n=97 
(39%); IG 
n=53; CG n=44 
Female: n=84 
Age: μ59±10 
years 
Cancer: n=119 
lung, n=86 head 
and neck, n=21 
bladder, n=18 
other 
History of 
CINV: No 
Reasons for 
attrition: n=25 
adverse events 
(IG n=13, CG 
n=12), n=24 
withdrew 
consent, n=1 
loss to follow-
up, n=2 
protocol 
violations, n=45 
other 
 
Drugs: 
Cisplatin >50m
g/m2 and other 
unspecified 
Emetogenicity: 
High 
Single or multi 
day: Single 
Commencing 
Cycle: Cycle 1 
Cycle length: 
n=140 were 21 
days. N=4 were 
28 days 
 
Aprepitant 
and 5-HT3 
receptor 
antagonist 
(Day 1); 
dexamethas
one (Days 
1-4) 
 
n: 125 
Type: Softel 
capsule with 
sunflower oil 
(110 mg) and 
zingiber 
officinalis 
standardised 
CO2 
supercritical 
extract 
(40mg); 
minimum 
Gingerols 
16mg, min 
Shogaol 
1.12mg 
Dose: 
0.16g/d 
(2x0.04g 
BD). 
Duration:  
42-56 days 
covering n=2 
Cycles, 
commenced 
on Day 2 of 
each 21-28-
day Cycle 
n: 126  
Type: 
Placebo of 
softgel 
capsule 
150mg 
sunflower oil 
 
CIN 
Any nausea incidence (VAS Score >5/100; OR <1.00 when IG had better protective effect 
against CIN that CG; measured daily): 
- C1 Day 2 to 5: IG n=77/121; CG n=71/123; OR: 1.06 (95% CI 0.60-1.85); P=0.851 
- C2 Day 2 to 5: IG n=52/121; CG n=55/123; OR: 1.36 (95% CI 0.69-2.70); P=0.379 
- Overall and Delayed Incidence (mean of C1 and C2 Day 2-5):b IG n=65/121 CG 
n=63/123 
- C1 Day 6 to 20 / 27 (Intercycle): IG n=66/121; CG n=60/123; OR: 1.31 (95% CI 0.73-
2.37); P=0.367 
- C2 Day 6 to 20 / 27 (Intercycle): IG n=46/121; CG n=47/123; OR: 1.32 (95% CI 0.68-
2.58); P=0.417 
- C1 Day 21 / 28 (Anticipatory): IG n=30/121; CG n=29/123; OR: -0.93 (95% CI 0.51-
1.72); P=0.823 
- C2 Day 21 / 28 (Anticipatory): IG n=20/121; CG n=22/123; OR: -1.20 (95% CI 0.58-
2.47); P=0.629 
Physical function 
FLIE Score (score ranges 18-126; higher scores indicate better physical function; measured 
on Days 1 and 6 of Cycle 1 and 2): 
- No difference between groups (data not reported) 
Fatigue  
BFI Score (score ranges 0-10; higher scores indicate more severe fatigue; measured on 
Days 1 and 6 of Cycle 1 and 2): 
- C1: treatment difference favouring ginger: 0.23, 95% CI:-0.97-0.51 
- C2: treatment difference favouring placebo: 0.09, 95% CI: –0.71-0.89 
Adverse Events: 
- 198 (78.9%) experienced 1 adverse event, no difference between groups (data not 
reported)  
- Adverse events related to study treatment: IG n=63/125 (51.1% mild, 33.1% moderate 
and 13.8% severe); CG n=35/126 (51.8% mild, 30.6% moderate and 15.6% severe) 
Mortality 
Not reported 
Danwilai 
2017 (35) 
 
Design: Pilot 
double-blind 
placebo-RCT 
Country: 
Thailand 
Recruitment 
Dates: 
September 
2012 to July 
2013 
N: 50 
Attrition: n=7 
(14%); IG n=6; 
CG n=1 
Female: n=43 
Age: 52.4 ± 9.1 
years  
Cancer: Breast 
(91%), ovarian 
and lung 
History of 
CINV: No 
Reasons for 
attrition: n=3 
withdrew 
consent, n=1 
unable to 
swallow 
capsule, n=3 
transferred to 
different site 
Drugs: Mostly 
anthracycline 
based regimen 
or some 
platinum based 
regimen. 
Emetogenicity: 
Moderate or 
high  
Single or multi 
day: Not 
specified 
Commencing 
Cycle: Cycle 1 
Cycle length: 
Not specified 
Dexametha
sone and 
ondansetro
n prior to 
CTx 
administrati
on. Rescue 
anti-
emetics at 
any time if 
needed.  
Those 
given 
aprepitants 
not eligible 
for 
inclusion 
n: 25 
Type: 
Capsule with 
0.005g 
standardised 
6-gingerol 
(1.4% w/w of 
ginger 
extract); 
binder; 
thickening  
agent  
Dose: 0.02g/d 
(2x 0.005g 
BD). 
Duration: 
from 3 days 
prior to CTx 
through to the 
4th Cycle 
n: 25 
Type: placebo 
capsule with 
binder, 
thickening 
agent and 
matched 
weight 
 
Adverse Events: 
- Withdrawals: IG 6; CG 1 
- Toxicity (n withdrawn due to unacceptable toxicity): IG n=0/25; CG not specified 
- Adverse events reasonably related to study treatment: IG n=0/19; CG not specified 
Mortality 
Not reported 
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Konmun 
2017 (36) 
 
Design:  
Double-blind 
placebo-
controlled 
randomised 
trial  
Country: 
Thailand  
Recruitment 
Dates: 
January 2012 
to July 2013 
 
N: 88 (n=94 
randomised but 
n-88 
commenced 
study) 
Attrition: 7 
(8%) 
Female: n=75 
Age: median 53 
(range 19-81) 
years 
Cancer: Solid 
tumors; breast 
cancer (72%); 
with prior 
surgical 
removal 
History of 
CINV: No 
Reasons for 
attrition: n=1 
protocol 
violation, n=6 
withdrew 
consent 
Drugs: 68% 
anthracycline-
based, 21% 
platinum-based. 
Emetogenicity: 
Moderate or 
high 
Single or multi 
day: Not 
specified 
Commencing 
Cycle: Cycle 1 
Cycle length: 
Not specified 
Ondansetro
n and 
dexamethas
one prior to 
CTx (IV 
Day 1, PO 
Days 1-4); 
PO 
Metoclopra
mide (days 
2-4). Those 
given 
aprepitants 
not eligible 
for 
inclusion 
 
n: 46 
Type:  
Capsule with 
0.005g 
standardised 
6-gingerol 
(1.4% w/w of 
ginger 
extract) 
Dose: 0.02g/d 
(2x0.005g 
BD) 
Duration: 
from 
3 days prior 
to CTx for at 
least 3 Cycles 
(through to 12 
weeks of 
treatment or 
completion of 
planned CTx) 
 
n: 42  
Type: 
Placebo - 
capsules with 
diluents/binde
r and 
thickening 
agent 
CIN 
Incidence (time points unclear): 
- All grade combined nausea: IG n=30/40; CG n=37/41; P=0.084 
- All grade acute nausea: IG n=18/40; CG n=30/41; P=0.010 
- All grade delayed nausea: IG n=30/40; CG n=37/41; P=0.084 
Severity (NRS ESAS Score; score ranges 0-10; higher scores indicate more severe CIN; 
measured daily 0-120hr post CTx): 
- Mild nausea: IG 55%; CG 17%; P<0.001 
- Moderate nausea: IG 15%; CG 39%; P<0.001 
- Severe nausea: IG 5%; CG 34%; P<0.001 
CIV 
Incidence (measured daily): 
- All grade combined vomiting: IG n=9/40; CG n=28/41; P<0.001 
- All grade acute vomiting: IG n=5/40; CG n=18/41; P=0.002 
- All grade delayed vomiting: IG n=9/40; CG n=28/41; P=0.002 
Fatigue 
Incidence of all grades: 
- IG n=31/42; CG n=41/46; P=0.020 between groups   
QoL 
FACT-G Score (mean (SD); score ranges 0-108; higher score indicates better QoL; 
measured at end of study, Day 64 post CTx): 
- Total Score: IG 86.21 (13.6); CG 72.36 (18.9); P<0.001 
Adverse Events  
Incidence of events reasonably related to intervention: 
- Toxicity: IG n=0/42; CG n=0/46 
- Other: IG n=0/42; CG not specified 
Mortality 
Not reported 
Li 2018 (40) Design: 
Double-blind 
placebo-RCT 
Country: 
China  
Recruitment 
Dates: June 
2016 to 
March 2017 
 
N: 146 
Attrition: n=6 
(4%) (IG n=2, 
IG n=4) 
Female: n=40 
Age: IG 57 ± 7-
8 years 
Cancer: lung 
History of 
CINV: IG 59%, 
CG 66% 
Reasons for 
attrition: self-
reported lack of 
compliance n=6 
Drugs: Cisplatin 
68%, 
carboplatin 
26%, oxaliplatin 
6% 
Emetogenicity:  
Single or multi 
day: not 
specified 
Commencing 
Cycle: any 
Cycle length: 
any 
Standard 
antiemetic 
therapy 
(5HT3 
RA’s). 66% 
had 
aprepitants 
n: 71 
Type: 0.25g 
capsule with 
standardised 
dry ginger 
root powder 
with 0.013g 
(5%) 
gingerols 
Dose: 0.5g/d 
(2x0.25g BD) 
Duration: for 
5 days 
starting on 
first day of 
CTx 
n: 69 
Type: 0.25g 
placebo 
capsule with 
corn starch  
CIN 
Incidence (measured on Day 2 and 5 post CTx):  
- Acute: IG n=49/71; CG n=39/69; P=0.174 
- Delayed: IG n=43/71; CG n=50/69; P=0.214 
- Overall Incidence (mean of acute and delayed):b IG 46/71; CG 45/69 
Severity Score (median MAT score (interquartile range); measured on Day 2 and 5 post 
CTx): 
- Acute: IG 3 (0, 4); CG 3 (0, 4); P=0.246 
- Delayed: IG 1 (0, 5); CG 2 (0, 4.5); P=0.347 
CIV 
Incidence (measured on Day 2 and 5 post CTx): 
- Acute: IG n=6/71; CG n=11/69; P=0.309 
- Delayed: IG n=16/71; CG n=18/69; P=0.813 
- Overall Incidence (mean of acute and delayed):b IG 11/71; CG 15/69 
Frequency (median MAT score (interquartile range); measured on Day 2 and 5 post CTx): 
- Acute: IG 0 (0, 0); CG 0 (0, 0); P=0.256 
- Delayed: IG 0 (0, 1); CG 0 (0, 0); P=0.718 
QoL 
FACT-G Score (mean (SD); score ranges 0-108; higher score indicates better QoL; 
measured on Day 1 and 5 post CTx): 
- Day 1: IG 72.65 (14.00); CG 71.78 (14.68); P=0.720 
- Day 5: IG 72.79 (14.00); CG 72.45 (13.93); P=0.884 
Adverse Events 
Incidence of events reasonable related to intervention (measured anytime during study 
duration): 
- Drowsiness: IG n=30/71; CG n=21/69; P=0.163 
- Dry mouth: IG n=18/71; CG n=9/69; P=0.086 
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- Heartburn: IG n=6/71; CG n=3/69; P=0.494 
- Flushing: IG n=11/71; CG n=5/69; P=0.184 
Mortality 
Not reported 
Marx 2017 
(41) 
 
Design: 
Double-blind 
placebo-RCT 
Country: 
Australia 
Recruitment 
Dates: March 
2014 to 
February 
2015 
 
N: 51 
Attrition: n=17 
(33%); n=9 IG; 
n=8 CG 
Female: n=32 
Age: 58 ± 12 
years 
Cancer: 37% 
colon, 26%, 
breast, 22% 
lymphoma, 
other. 
History of 
CINV: No 
Reasons for 
attrition: n=4 
adverse event 
(n=3 CG, n=1 
IG), n=3 
nausea/vomiting
, n=1 loss to 
follow-up, n=9 
withdrew 
consent 
 
Drugs: Not 
specified 
Emetogenicity: 
85% moderate, 
16% high 
Single or multi 
day: Single dayc 
Commencing 
Cycle: Cycle 1  
Cycle length: 
Not specified 
Standard 
anti-
emetics 
prescribed 
by 
physician 
not 
specified 
n: 24 
Type: 0.3g 
capsule 
standardised 
ginger extract 
with 5% 
(0.015g) 
gingerols  
Dose: 1.2g 
(0.3g QID) 
Duration: 5 
days starting 
on the day of 
CTx from 
Cycle 1-3 
n: 27 
Type: 0.3g 
placebo 
capsule with 
inert filler  
CIN  
INVR Score (median (IQR); score ranges 0-10; higher score indicates more severe CIN):   
- Acute (measured on the day of CTx) C1: IG 3.6 (3, 5); CG 3 (3, 5); P=0.46 
- Acute C2: IG 3 (3, 3); CG 3 (3, 4); P=0.63 
- Acute C3: IG 3 (3, 5); CG 3 (3, 5); P=0.79 
- Delayed (combination of scores measured from Day 1 post CTx to Day 5 post CTx) C1: 
IG 11 (9, 17); CG 15 (9, 20); P=0.27 
- Delayed C2: IG 14.5 (9, 15); CG 12 (9, 16); P=0.54 
- Delayed C3: IG 12 (9, 16.5); CG 12 (9, 16); P=0.42 
CIV  
INVR Score (median (IQR)):   
- Acute (measured on the day of CTx) C1: IG 3 (3, 3); CG 3 (3, 3); P=0.41 
- Acute C2: IG 3 (3, 3); CG 3 (3, 3); P=0.99 
- Acute C3: IG 3 (3, 3); CG 3 (3, 3); P=0.17 
- Delayed (combination of scores measured from Day 1 post CTx to Day 5 post CTx) C1: 
IG 9 (9, 9.7); CG 9 (9, 12); P=0.74 
- Delayed C2: IG 9 (9, 10); CG 9 (9, 10); P=0.95 
- Delayed C3: IG 9 (9, 9); CG 9 (9, 10); P=0.69 
CINV  
INVR Score (median (IQR); score ranges 0-10; higher score indicates more severe CINV): 
- Anticipatory (measured on the day before CTx) C1: IG 8 (8, 8); CG 8 (8, 8); P=0.44 
- Anticipatory C2: IG 8 (8, 9); CG 8 (8, 9); P=0.61 
- Anticipatory C3: IG 8 (8, 8); CG 8 (8, 9); P=0.76 
QoL  
CINV QoL (FLIE-5DR score; median (IQR); score ranges 18-126; higher scores indicate 
better QoL; measured at baseline and 4 days post CTx): 
- C1: IG 124.5 (113.2, 126); CG 111 (99, 126); P=0.043 between groups 
- C2: IG 124 (108, 126); CG 117 (109, 126); P=0.916 between groups 
- C3: IG 123.5 (107, 126); CG 120 (111, 126); P=0.931 between groups 
Global Cancer-related QoL (FACT-G score; mean (SD); score ranges 0-108); higher scores 
indicate better QoL; measured at baseline and 4 days post CTx): 
- C1: IG 85.1 (18.9); CG 71.9 (18.3); P=0.015 between groups 
- C2: IG 74.9 (17.7); CG 67.6 (10.2); P=0.077 between groups 
- C3: IG 83.6 (15.0); CG 75.1 (13.9); P=0.040 between groups 
- Overall (mean of C1 and C3)b: IG 81.2 (17.2); CG 71.6 (14.1) 
Fatigue 
FACIT-F score (mean (SD); score ranges 0-52, higher scores indicate less fatigue; 
measured at baseline and 4 days post CTx):  
- C1: IG 41.8 (13); CG 32.2 (10.8); P=0.006 between groups 
- C2: IG 37.7 (10.8); CG 34.5 (7.9); P=0.23 between groups 
- C3: IG 42.4 (10.2); CG 36.1 (7.2); P=0.013 between groups 
Adverse Events 
Incidence (measured 5-days post CTx): 
Overall adverse events not reasonable attributable to intervention: IG n=1/24; CG n=3/27 
Side effects reasonably related to study treatment: IG n=2/24 constipation, IG n=4/24 
reflux, CG not specified 
Mortality 
Not reported 
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Montazeri 
2013 (30) 
 
Design:  
Cross-over 
double 
blinded, 
placebo RCT 
Country: 
Unclear, 
possibly Iran 
Data 
Collection 
Dates: 
September 
2006 to 
March 2007 
 
N: 44 
Attrition: n=13 
(30%) during 
second 
intervention 
period, unclear 
from which 
groups. 
Female: n=18 
Age: mean 50.3 
± 3.1 years 
Cancer: mainly 
oesophagus  
History of 
CINV: Yes 
Reason for 
attrition: n=3 
death, n=7 
protocol 
violation, n=2 
vomiting, n=1 
loss to follow-
up 
Drugs: Cisplatin 
with or without 
other 
unspecified 
CTx  agents 
(most 
commonly 
fluorouracil 5) 
Emetogenicity: 
Not specified 
Single or multi 
day: Not 
specified 
Commencing 
Cycle: After 
Cycle >1, not 
specified  
Grainestron
e and 
dexamthaso
ne and 
metoclopra
mide if 
requested 
n: Unclear; 
possibly 37 
Type: 0.25g 
ginger 
powder 
capsule 
Dose: 1g/d 
(2x 0.25g 
BD) 
Duration: for 
one Cycle (at 
least 28 days) 
before 
crossing over 
n: Unclear; 
possibly 37 
Type: 0.25g 
placebo 
capsule with 
chickpea 
flour (2x 
0.25g BD)  
CINV  
Severity (Strain Tools of Severity; score ranges 0-10; higher score indicates more severe 
CIN; measured 7,8,9,10 and 24 hours post CTx): 
- C1: in the 7th, 8th, 9th, 10th and 24th hours post CTx, severity reduced 9.1%, 9.1%, 9.1% 
4.6% and 4.7% more in IG than CG, respectively. 
- C2: In the 8th, 9th, 10th and 24th hours post CTx, severity reduced 4%, 6.3%, 6.7% and 
8.3% more in the CG than IG, respectively. There was no significant difference in the 7th 
hour post CTx 
Mortality 
- n=3/37 
Muthia 2013 
(26) 
 
Design: 
Control time 
series  
Country: 
Indonesia 
Data 
Collection 
Dates: April 
2013 to May 
2013 
 
N: 20 
Attrition: n=0 
Female: n=20 
Age: unclear. 
Cancer: Breast 
History of 
CINV: Unclear 
Drugs: 
Cyclophospham
ide, 
Adriamycin-5-
fluorouracil 
Emetogenicity: 
Not specified 
Single or multi 
day: Not 
specified 
Commencing 
Cycle: Not 
specified 
Cycle length: 
Not specified 
Ondasentro
n and 
dexamethas
one 
n: 10 
Type: Self-
prepared 
ginger 
infusion (10g 
fresh Zingiber 
officanale 
varietas 
rubrum 
[pared and 
grated] + 
100mL water 
to make. 
Infused for 15 
minutes 
starting at 
90’C, strained 
and diluted to 
150ml. 
Dose: 1 serve 
[unclear if 
15ml or 
150ml] x3/d 
Duration: Not 
specified, 
from the 2nd 
day after CTx  
n: 10 
Type: no 
intervention /  
standard care  
CINV  
INVR (score ranges 0-10; higher score indicates more severe CINV; time point unclear): 
- IG decrease in score P=0.000; CG decrease in score P=0.011 
- Difference between IG and CG P=0.036 
Mortality 
Not reported 
 
 
Sanaati 2016 
(31) 
 
Design: 
Double blind 
RCT 
Country: Iran 
N: 43 
Attrition: n=13 
(30%); n=7 IG; 
n=5 CG 
Drugs: Not 
specified 
Emetogenicity: 
Not specified  
Dexametha
sone, 
metoclopra
mide and 
aprepitant 
n: 23 
Type: 0.5g 
capsule 
powdered 
ginger root 
n: 20 
Type: 
Standard Care 
(no ginger) 
 
CIN  
Incidence (self-designed tool; measured every night from 5 days before to 5 days after 
CTx):  
- Mean difference between groups 1.5 (S.E. 0.58); P=0.006 
CIV  
 50 
Recruitment 
Dates: May 
2013 to June 
2014 
 
 
Female: Not 
specified 
Age: range 20-
60 years 
Cancer: Breast 
History of 
CINV: Yes 
Reasons for 
attrition: CTx 
cancelled, 
withdrew, not 
completing data 
collection, death 
(numbers per 
group unclear) 
Single or multi 
day: Single  
Commencing 
Cycle: ≥ Cycle 
2 
Cycle length: 
≥2 weeks 
 
(DMA) 
capsule 
 
Dose:  
1g/d (0.5g 
BD) 
Duration: 10 
days (from 5 
days before to 
5 days after 
CTx) 
 
Incidence (self-designed tool; measured every night from 5 days before to 5 days after 
CTx):  
- Mean difference between groups 0.11 (S.E. 0.25); P<0.0001 
Mortality 
Not reported 
 
 
Shokri 2017 
(32) 
 
Design: 
Double blind, 
placebo RCT  
Country: Iran 
Data 
Collection 
and Analysis 
Dates: 
October 2014 
to February 
2015 
 
N: 49 
Attrition: n=0 
Female: n=49 
Age: mean 53 ± 
11-16 years. 
Cancer: Stage I 
to III ovarian 
cancer who had 
undergone 
cytoreductive 
surgery 
History of 
CINV: Not 
specified 
Drugs: 
Carboplatin and 
paclitaxel 
Emetogenicity: 
Not specified 
Single or multi 
day: Not 
specified  
Commencing 
Cycle: Not 
specified 
Cycle length: 21 
days 
Not 
specified 
n: 20  
Type: 1g 
capsule 
Dose: 2g/d 
(1g BD) 
Duration: for 
6 Cycles 
n: 29 
Type: 1g 
placebo 
capsule  
Dose: 2g/d 
(1g BD) 
Duration: for 
6 Cycles 
CINV 
Incidence (time point not specified): 
- IG n=8/20; CG n=14/29; P=0.57 between groups 
Adverse Events  
Incidence (measured at the end of treatment up to 12 months after baseline): 
- hematologic, renal and digestive complications (unspecified): IG n=10/20; CG n=21/29; 
P=0.11 between groups 
- weight loss: IG n=1/20; CG n=1/29; P=0.66 between groups 
- peripheral neuropathy: IG n=3/20; CG n=5/29; P=0.58 between groups 
- bone marrow depression: IG n=2/20; CG n=2/29; P=0.54 between groups 
- transient cortical blindness: IG n=1/20; CG n=0/29; P=0.41 between groups 
- peripheral neuropathy: IG n=3/20; CG n=5/29; P=0.58 between groups 
Mortality 
Incidence (during 12-month follow up period): 
- IG n=2/20; CG n=3/29; P=0.68 between groups 
Thamlikitkul 
2017 (37) 
 
Design: 
Double blind, 
placebo-
controlled 
crossover 
RCT 
Country: 
Thailand  
Recruitment 
Dates: 
February 
2015 to 
December 
2015 
N: 34 
Attrition: 0 
Female: n=34 
Age: mean 49 
(range 32-68) 
years 
Cancer: Breast 
History of 
CINV: Yes 
Drugs: 
Cyclophospham
ide and 
doxorubicin 
Emetogenicity: 
High 
Single or multi 
day: Not 
specified  
Commencing 
Cycle: 
Cycle 2 
Cycle length: 
Not specified 
  
Ondansetro
n and 
dexamethas
one and 
rescue 
domperidon
e or 
metoclopra
mide  
if needed 
 
n: 34 
Type: 
capsuled dry 
ginger 
powder  
Dose: 1g 
(0.5g BD) 
Duration: 5 
days starting 
on Day 1 of 
CTx for one 
Cycle then 
crossed over 
to second 
group for the 
next Cycle 
n: 34 
Type: 
Placebo 
capsule 
Dose: 0.5g 
BD 
Duration: 5 
days starting 
on Day 1 of 
CTx for one 
Cycle then 
crossed over 
to second 
group for the 
next Cycle 
 
CIN  
Severity (VAS score; score ranges 0-100; higher score indicates worse symptoms; 
measured once daily for 5 days starting on day 1 of CTx): 
- Maximum Nausea Score: IG 35.36 (S.E. 4.43); CG 32.17 (S.E. 3.71); difference between 
groups 3 (95% CI -3-9), P=0.3 
- Acute Nausea Score: IG 25.00 (S.E. 4.70); CG 23.00 (S.E. 3.40); difference between 
groups 2 (95%CI -6-9), P=0.64 
- Delayed nausea score: IG 25.95 (S.E.3.64); CG 23.08 (S.E. 3.12); difference between 
groups 2.9 (95%CI -2-7.4), P=0.21 
CIV  
Incidence (measured once daily for 5 days starting on day 1 of CTx): 
- IG n=9/34; CG n=10/34; P=0.5 between groups 
Fatigue 
Incidence of all grades (measured once daily for 5 days starting on day 1 of CTx): 
- IG n=25/34; CG n=21/34 
Adverse events 
Incidence of Grade ≥3 (measured once daily for 5 days starting on day 1 of CTx): 
- Febrile Neutropaenia: IG n=0/34; CG n=1/34 
- Neutropaenia: IG n=2/34; CG n=1/34 
Mortality 
Not reported 
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Yekta 2012 
(33) 
 
Design: 
Double blind, 
placebo-RCT 
Country: Iran 
Study 
Duration 
Dates: July 
2009 to 
December 
2009 
N: 98  
Attrition: n=18 
(18%); unclear 
from which 
groups. 
Female: n=80 
Cancer: Breast 
History of 
CINV: Yes 
Reasons for 
attrition: 
cancelled CTx, 
withdrew, did 
not complete 
data collection, 
death. Unclear 
numbers from 
each group. 
Drugs: Not 
specified 
Emetogenicity: 
84% moderate 
to high 
Single or multi 
day: Single  
Commencing 
Cycle: 
≥ Cycle 2 
Cycle length: ≥ 
2 weeks 
 
Kytril or 
Granisetron 
hydrochlori
de tablets 
and 
dexamethas
one  
 
n: 40 
Type: 0.25g 
ginger root 
capsules, dry 
ginger root 
(5.38mg 6-
gingerol, 
1.8mg 8-
gingerol, 
4.19mg 10-
gingerol, 
0.92mg 6-
shagaol) 
Dose: 1g 
(0.25g QID) 
Duration: For 
6 days from 3 
days before 
CTx session 
n: 40 
Type: 
Placebo 
capsule 
Dose: 
0.25g QID 
made with 
starch 
Duration: For 
6 days from 3 
days before 
CTx session 
CIV  
Incidence (mean (SD); measured daily for 6 days starting 3 days before CTx): 
- Anticipatory: IG n=0.5/40 (0.3); CG n=1.5/40 (5.9); P=0.04 between groups 
- Acute: IG 2.7/40 (1.2); CG n=3.7/40 (2.5); P=0.04 between groups 
- Delayed: IG 3.3/40 (1.1); CG n=7.9/40 (3.9); P=0.003 between groups 
- Total: IG 2.3/40 (5.1); CG 7.9/40 (14); P=0.002 between groups 
Adverse Events 
Incidence (no time point specified): 
- Heartburn Acute: IG n=5/40; CG n=0/40; P=0.06 between groups 
- Heartburn Delayed: IG n=2/40; CG n=0/40; P=0.5 between groups 
- Heartburn Overall (mean of acute and delayed):b IG 4/40; CG 0/40 
Mortality 
Not reported 
 
 
BFI: Brief Fatigue Inventory; CIN: Chemotherapy-induced nausea; CIV: Chemotherapy-induced vomiting; CINV: Chemotherapy-induced nausea and vomiting; CTx: chemotherapy; d: day; FACIT-F: Functional Assessment of Chronic Illness 
Therapy-Fatigue; FACT-G: Functional Assessment of Cancer Therapy-General; FLIE: Functional Living Index Emesis; FLIE-5DR: Functional Living Index Emesis 5 Day Recall; INVR: Rhodes Inventory of Nausea, Vomiting and Retching; 
MAT: Multinational Association of Supportive Care in Cancer (MASCC) Antiemesis Tool; NRS ESAS: Numerical Rating Scale using Edmonton’s Symptom Assessment Scale; n: number; QoL: Quality of Life; RCT: Randomised Controlled 
Trial; VAS: Visual analogue scale. 
a Data tables not published, therefore data unclear. 
b This was calculated by review authors to generate a number used for meta analyses. 
c Information supplied by author. 
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Table 2. Included studies located in the researchers’ previous systematic review (n=5), examining the effect of ginger supplementation on chemotherapy-
induced nausea and vomiting incidence and chemotherapy-related outcomes. 
Citation Study Design & Setting Population  CTx Protocol 
Adjuvant 
Therapies 
Intervention 
Group/s (IG) 
Comparator 
Group/s 
(CG)  
Results  
Fahimi 
2011 
(28) 
 
Design:  
Double blind 
crossover 
placebo RCT 
Country: Iran 
Dates: Not 
specified 
 
N: 50 
Attrition: 
n=14  
Female: n=10 
Age: mean 
50.2  ± 12.2 
years 
Cancer: lung 
(50%), others 
not specified 
History of 
CINV: Not 
specified  
Drugs: 
Cisplatin with 
at least one of: 
etoposide, 
docetaxel, 
gemcitabine, 
docetaxel, 
vinorelbine, 
cyclophospham
ide, 
paclitaxel, 
doxorubicin, 5-
FU, 
pemetrexed 
Emetogenicity: 
Not specified. 
Single or multi 
day: Unclear 
Commencing 
Cycle: Not 
specified 
Cycle length: 
Not specified 
5-HT3 
antagonist 
(granisetrone) 
and 
corticostreoid 
(hydrocortiso
ne) 
n: 36 
Type: 0.25g 
capsule, powdered 
ginger (Zintoma) 
Dose: 1g (2x 
0.25g BD) 
Duration: 3 days 
starting on the day 
of CTx then a 3-
week washout 
period prior to 
cross over 
 
n: 36 
Type: 0.25g 
placebo 
capsule 
composed of 
lactose. 
Dose: 1g (2x 
0.25g BD  
Duration: 3 
days starting 
on the day of 
CTx then a 3-
week washout 
period prior 
to cross over 
 
CIN  
Incidence (measured 24, 48 and 72hr post CTx): 
- Day 1 (Acute Incidence): IG n=17/36; CG n=21/36; P=0.388 between groups 
- Day 2: IG n=16/36; CG n=19/36; P=0.508 between groups 
- Day 3: IG n=17/36; CG n=18/36; P<0.999 between groups 
- Overall Incidence (mean of Day 1-3):a IG n=17/36; CG n=19/36 
- Delayed Incidence (mean of Day 2-3):a IG n=17/36; CG n=19/36 
Severity Score (MANE Score; mean (SD); score ranges 1-7; higher score indicated more 
severe CIN): 
- Day 1 (acute severity): IG 1.75 (2.02); CG 1.36 (1.91); P=0.14 between groups 
- Day 2: IG 1.78 (1.93); CG 1.50 (2.03); P=0.31 between groups 
- Day 3: IG 1.61 (1.93); CG 1.47 (1.92); P=0.73 between groups 
- Overall Severity (mean of Day 1-3 scores):a IG 1.71 (1.96); CG 1.44 (1.95) 
- Delayed Severity (mean of Day 2-3 scores):a IG 1.7 (1.93); CG 1.49 (1.98) 
CIV 
Incidence (measured 24, 48 and 72hr post CTx): 
- Day 1 (acute incidence): IG n=21/36; CG n=27/36; P=0.070 between groups 
- Day 2: IG n=27/36; CG n=29/36; P=0.687 between groups 
- Day 3: IG 29/36; CG 28/36; P<0.999 between groups 
- Overall Incidence (mean of Day 1-3):a IG n=26/36; CG n=28/36 
- Delayed Incidence (mean of Day 2-3):a IG n=28/36; CG n=29/36 
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Severity Score (MANE Score; mean (SD); score ranges 1-7; higher score indicated more 
severe CIV): 
- Day 1: IG 1.47 (2.18); CG 0.94 (1.77); P=0.14 between groups 
- Day 2: IG 1.03 (1.89); CG 0.83 (1.84); P=0.72 between groups 
- Day 3: IG 0.80 (1.83); CG 0.92 (1.86); P=0.78 between groups 
Mortality 
Not reported 
Manusi-
rivithaya 
2004 
(34) 
 
Design:  
Double blind 
crossover 
RCT 
Country: 
Thailand 
Dates: Not 
specified 
N: 48  
Attrition: n=5 
Female: n=43 
Age: mean 
46±10-14 
years 
Cancer: ovary 
(76%), 
cervical 
(23%) 
History of 
CINV: Not 
specified 
Drugs: 
Cisplatin with 
one of the 
following 
agents: 
cyclophospham
ide, 
ifosfamide, 
etoposide, 
bleomycin, 5-
fluorouracil 
Emetogenicity: 
High 
Single or multi 
day: Unclear 
Commencing 
Cycle: Not 
specified 
Cycle length: 
Not specified 
Metocloprami
de (Day 1 30 
min before 
CTx), 
dexamethason
e and 
lorazepam 
(Day 1 30 
min before 
and 6 h after 
CTx) 
n: 43 
Type: 0.25g 
capsule, ginger 
root powder  
Dose: 1g (0.25g 
QID) 
Duration: 5 days 
then a 3-4 week 
washout period 
prior to cross over 
n: 43 
Type: 0.25g 
placebo 
capsule (corn 
starch) 
Dose: 1g 
(0.25g QID) 
Duration: 5 
days then a 3-
4 week 
washout 
period prior 
to cross over  
CIN 
Severity (VAS Score; mean (SD); score ranges 0-10; higher score indicates more severe 
CIN; recorded daily on Days 1-5): 
- Day 1 (acute severity): IG 4.32 (3.61); CG 4.31 (3.31); P=0.875 between groups 
- Day 2: IG 4.23 (3.30); CG 3.84 (3.01); P=0.582 between groups 
- Day 3: IG 4.01 (3.65); CG 4.20 (3.71); P=0.865 between groups 
- Day 4: IG 2.67 (3.23); CG 2.99 (3.30); P=0.294 between groups 
- Day 5: IG 2.14 (2.89); CG 1.89 (2.73); P=0.554 between groups 
- Overall Severity (mean of Day 1-5 scores):a IG 3.47 (3.34); CG 3.45 (3.21) 
- Delayed Severity (mean of Day 2-5 scores):a IG 3.26 (3.27); CG 3.23 (3.19) 
CIV  
Incidence (recorded daily on Days 1-5) 
- >5 episodes: IG n=8/43; CG n=9/43; P=0.754 
- 3-5 episodes: IG n=4/42; CG n=5/43; P=0.754 
- 1-2 episodes: IG n=15/43; CG n=11/43; P=0.754 
- Overall Incidence (sum of 1->5 episodes):a IG 27/43; CG 25/43 
Side Effects 
Incidence: 
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- Any relatable side effects: IG n=12/43; CG n=8/43; P=0.503 between groups 
- Restlessness: IG n=8/46; n=CG 2/46; P=0.109 between groups 
- Diarrhoea: IG n=2/46; CG n=6/46; P=0.289 between groups 
- Constipation: IG n=6/46; CG n=3/46; P=0.508 between groups 
- Headache: IG n=3/46; CG n=1/46; P=0.625 between groups 
- Dizziness: IG n=5/46; CG n=6/46; P=1.000 between groups 
- Heartburn: IG n=3/46; CG n=3/46; P=1.000 between groups 
- Palpitation: IG n=1/46; CG n=1/46; P=1.000 between groups 
- Akathisia: IG n=1/46; CG n=0/46 
- Acute Dystonic Reaction: CG n=1/46; CG n=0/46 
Mortality 
Not reported 
Panahi 
2012 
(29) 
 
Design: Open 
pilot RCT  
Country: Iran 
Study 
Duration 
Dates: July 
2008 to 
November 
2009 
N: 100  
Attrition: 
n=22 
Female: n=78 
Age: mean 
58.1±9.2 
years 
Cancer: 
Mainly 
advanced 
breast 
History of 
CINV: Not 
specified 
Drugs: 
Predominately 
TEC  
(docetaxel, 
epirubicin,  
cyclophospham
ide) 
Emetogenicity: 
Moderate or 
High  
Single or multi 
day: Not 
specified 
Commencing 
Cycle: Mainly 
Cycle 1 
Standard 
antiemetic 
regimen 
(granisetron 
and 
dexamethason
e) 
 
n: 37 
Type: 0.5g 
capsule powdered 
ginger root 
Dose: 1.5g (0.5g 
TID) 
Duration: 5 days 
from the day of  
CTx. Number of 
Cycles 
unspecified 
 
n: 41 
Type: Usual 
care 
 
 
CIN 
Incidence: 
- <6 hours: IG n=9/37; CG n=17/41; P=0.11 between groups 
- 6-24 hours: IG n=13/37; CG n=24/41; P=0.04 between groups 
- Day 2: IG n=17/37; CG n=22/41; P=0.43 between groups 
- Day 3: IG n=20/37; CG n=22/41; P=0.93 between groups 
- Day 4: IG n=21/37; CG n=19/41; P=0.42 between groups 
- Overall Incidence (mean of <6hrs, 6-24hrs and Day 2-4):a IG n=16/37; CG n=21/41 
- Acute Incidence (mean of <6hrs and 6-24hrs):a IG n=11/37; CG n=21/41 
- Delayed Incidence (mean of Day 2-4):a IG n=19/37; CG n=31/57 
CIV  
Incidence (combined with retching): 
- <6 hours: IG n=9/37; CG n=11/41; P=0.80 between groups 
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Cycle length: 
Not specified 
- 6-24 hours: IG n=7/37; CG n=12/41; P=0.26 between groups 
- Day 2: IG n=13/37; CG n=11/41; P=0.47 between groups 
- Day 3: IG n=13/37; CG n=12/41; P=0.63 between groups 
- Day 4: IG n=16/37; CG n=14/41; P=0.46 between groups 
- Overall Incidence (mean of <6hrs, 6-24hrs and Day 2-4):a IG 12/37; CG 12/41 
- Acute Incidence (mean of <6hrs and 6-24hrs):a IG n=8/37; CG n=12/41 
- Delayed Incidence (mean of Day 2-4):a IG n=14/37; CG n=12/57 
CINV 
RINVR (Mean Score (SD); score ranges 0-24; higher score indicates more severe CINV): 
- <6 hours: IG 3.22 (4.45); CG 2.98 (3.95); P=0.80 between groups 
- 6-24 hours: IG 3.11 (4.04); CG 4.10 (4.42); P=0.31 between groups 
- Day 2: IG 4.35 (4.84); CG 4.32 (4.36); P=0.98 between groups 
- Day 3: IG 4.78 (4.82); CG 4.22 (5.06); P=0.62 between groups 
- Day 4: IG 5.70 (5.60); CG 4.47 (5.45); P=0.33 between groups 
Mortality 
Not reported 
Ryan 
2012 
(27) 
 
Design: 
Double blind, 
placebo RCT 
Country: USA 
Recruitment 
Dates: June 
2002 to 
December 
2008 
N: 371 
 Attrition: 
n=88 (IG 
n=49; CG 
n=39) 
Female: 
n=257 
Age: mean 
53-54 (S.E. 1) 
Cancer: 
Breast (56%); 
Drugs: Not 
specified 
Emetogenicity: 
Any 
Single or multi 
day: Not 
specified 
Commencing 
Cycle: ≥ Cycle 
2 
Cycle length: 
Not specified 
5-HT3 
receptor 
antagonist. 
dexamathason
e at all CTx 
Cycles 
 
n: 134 
Type 1: 0.25g 
capsule ginger 
liquid extract of 
ginger root (8.5mg 
of combined 
gingerols, 
zingerone and 
shogoal) with 
olive oil 
containing other 
unspecified 
excipients to 
improve 
solubilisation and 
n: 149 
Type: 0.25g 
placebo 
capsule with 
olive oil and 
excipients 
Dose: 1.5g 
(3x0.25g BD) 
Duration: 6 
days, starting 
three days 
before CTx. 
CIN 
Severity Score (LS mean change (SE); score ranges 1-7; higher score indicated more 
severe CIN; measured at 4 times daily from Days 1-4 of each Cycle): 
- Average Nausea All IG’s vs CG: -0.350 (-0.140); P=0.013 
- Average Nausea: IG -0.441 (0.127); CG 0.015 (0.121); P=0.046 between groups 
Quality of Life  
FACIT-G Score (score ranges 0-108; higher score indicates better QoL; measured at Day 
1 and Day 4 of each Cycle): 
- no significant difference between groups 
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GI (7%); lung 
(5%)  
History of 
CINV: Yes  
 increase 
bioavailability 
Type 2: Placebo 
capsule with olive 
oil and excipients 
Dose: 
0.5g/d (0.25g and 
x4 placebo) 
Duration: 6 days, 
starting three days 
before CTx 
Adverse Events  
Time point not specified: 
- n=24/745 (all four groups). Related to study intervention (n=9/557) (GI symptoms: 
Grade 2 heartburn, bruising/flushing, rash; not delineated between treatment doses) 
- Gastrointestinal symptoms: IG n=5/183; CG n=5/188 
Mortality 
Not reported 
 
N: 375 
 Attrition: 
n=95 (IG 
n=49; CG 
n=46) 
Female: 
n=257 
Age: mean 
52-53 (S.E. 1) 
Cancer: 
Breast (56%); 
GI (6%); 
gynecologic 
(5%)  
History of 
CINV: Yes 
As per above As per above n: 141 
Type 1: 0.25g 
capsule ginger 
liquid extract of 
ginger root (8.5mg 
of combined 
gingerols, 
zingerone and 
shogoal) with 
olive oil 
containing other 
unspecified 
excipients to 
improve 
solubilisation and 
increase 
bioavailability 
Type 2: Placebo 
capsule with olive 
oil and excipients 
Dose: 1g/d of 
ginger (x4 0.25g 
and x2 placebo) 
Duration: 6 days, 
starting three days 
before CTx 
As per above. CIN  
Severity Score (score ranges 1-7; higher score indicated more severe CIN; measured at 4 
times daily from days 1-4 of each Cycle): 
- Average Nausea: IG LS Mean Change -0.402, SE 0.124; CG 0.015, SE 0.121; P=0.076 
between groups 
Quality of Life  
FACIT-G Score (score ranges 0-108; higher score indicates better QoL; measured at day 1 
and day 4 of each Cycle): 
- no significant difference between groups 
Adverse Events  
Time point not specified: 
- n=24/745 (all four groups). Related to study intervention (n=9/557) (GI symptoms: 
Grade 2 heartburn, bruising/flushing, rash; not delineated between treatment doses) 
- Gastrointestinal symptoms: IG n=7/187; CG n=5/188 
Mortality 
Not reported 
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N: 375 
 Attrition: 
n=74 (IG 
n=35; CG 
n=39) 
Female: 
n=277 
Age: mean 
52-53 (S.E. 1) 
Cancer: 
Breast (60%); 
GI (6%); lung 
(5%)  
History of 
CINV: Yes 
As per above As per above n: 152 
Type 1: 0.25g 
capsule ginger 
liquid extract of 
ginger root (8.5mg 
of combined 
gingerols, 
zingerone and 
shogoal) with 
olive oil 
containing other 
unspecified 
excipients to 
improve 
solubilisation and 
increase 
bioavailability 
Dose: 1.5g/d (x6 
0.25g; no 
placebo). 
Duration: 6 days, 
starting three days 
before CTx 
As per above. CIN  
Severity Score (score ranges 1-7; higher score indicated more severe CIN; measured at 4 
times daily from Days 1-4 of each Cycle): 
- Average Nausea: IG C LS Mean Change -0.158, SE 0.120; CG 0.015, SE 0.121; 
P=0.738 between groups 
Quality of Life  
FACIT-G Score (score ranges 0-108; higher score indicates better QoL; measured at day 1 
and day 4 of each Cycle): 
- no significant difference between groups 
Adverse Events 
Time point not specified: 
- n=24/745 (all four groups). Related to study intervention (n=9/557) (GI symptoms: 
Grade 2 heartburn, bruising/flushing, rash; not delineated between treatment doses) 
- Gastrointestinal symptoms: IG n=9/187; CG n=5/188 
Mortality 
Not reported 
 
Zick 
2009 
(38) 
 
Design:  
Double blind 
Placebo RCT 
Country: USA 
Study 
Duration 
Dates: June 
2003 and May 
2006 
N: 110 
Attrition: 
n=21 (IG 
n=10; GC 
n=11) 
Female: n=92 
Age: mean 
53-55±11-12 
years 
Cancer: Not 
specified 
Drugs: 20 
different 
regimens 
specified in 
publication 
Emetogenicity: 
17% high; 65% 
moderate. 
Single or multi 
day: Single 
Commencing 
Cycle: ≥ Cycle 
2 
Apripetant, 5-
HT3 receptor 
antagonist 
(Dolasetron, 
Granistron, 
Ondansetron 
or 
Palonosetron) 
n: 53 
Type: 0.25g 
capsule dry 
extract of ginger 
root (10:1 (v/v) 
extraction solvent 
(ethanol 
50%)/root) 
standardized to 15 
mg (5%) of total 
gingerols. 5.38 mg 
(2.15%) 6-
gingerol, 1.80 mg 
(0.72%) 8-
gingerol, 4.19 mg 
(1.78%) 10-
gingerol, and 0.92 
n: 57 
Type: 
Placebo 
capsules with 
lactose 
powder 
Dose: 8/day 
Duration: 3 
days starting 
on day of 
CTx 
administratio
n 
CIN 
Incidence: 
- <24hr post CTx (acute incidence): IG n=33/53; CG n=31/57; P=0.86 between groups 
- 24-48hr post CTx (delayed incidence): IG n=37/53; CG n=31/57; P=0.16 between 
groups 
- Overall (mean of <24hrs and 24-48hrs):a IG n=35/53; CG n=31/57 
Severity (MANE Score; mean (SD); score ranges 1-7; higher score indicated more severe 
CIN): 
- <24hr post CTx, no aprepitant: IG 3.1 (1.2) CG 2.8 (1.3); P=0.47 
- <24hr post CTx, aprepitant: IG 2.8 (1.1); CG 3.1 (1.5); P=0.55 
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History of 
CINV: Yes 
 
 
 
Cycle length: 
Not specified 
  
mg (0.37%) 6-
shogaol. 
AND placebo 
capsules. 
Dose:  
1g/d (4x 0.25g + 
4x placebo) 
Duration: 3 days 
starting on day of 
CTx 
administration 
 - 24-48hr post CTx, no aprepitant: IG 3.0 (1.1); CG 3.0 (1.3); P=0.69 
- 24-48hr post CTx, aprepitant: IG 2.9 (1.3); CG 2.2 (0.7); P=0.01 
- Overall (mean of <24hr and 24-48hr scores):a IG 2.95 (1.18); CG 2.78 (1.2) 
- Acute Severity (mean of <24hr scores):a IG 2.95 (1.15); CG 2.95 (1.4) 
- Delayed Severity (mean of 24-48hr scores):a IG 2.95 (1.2); CG 2.6 (1) 
CIV 
Incidence: 
- <24hr post CTx (acute incidence): IG n=19/53; CG n=14/57; P=0.47 between groups 
- 24-48hr post CTx (delayed incidence): IG n=19/53; CG n=9/57; P=0.07 between groups 
- Overall Incidence (mean of <24hrs and 24-48hrs):a IG n=19/53; CG n=12/57 
Severity (MANE Score; mean (SD); score ranges 1-7; higher score indicated more severe 
CIV): 
- 24hr post CTx, no aprepitant: IG 3.1 (1.4); CG 3.6 (1.4); P=0.61 
- 24hr post CTx, aprepitant: IG IG 3.4 (0.6); CG 4.0 (1.7); P=0.91 
- 24-48hr post CTx, no aprepitant: IG 2.7 (0.9); CG 4.0 (1.3); P=0.88 
- 24-48hr post CTx, aprepitant: IG 3.0 (1.4); CG 3.0 (0.0); P=0.77 
Adverse Events  
Occurring within the 3-day study period: 
- Fatigue: IG n=1/53; CG n=5/57; P=0.03 
- Laboratory abnormalities: IG n=8/53; CG n=8/57; P=0.06 
- Miscellaneous: IG n=3/53; CG n=8/57; P=0.02 
Mortality 
Not reported 
N: 109 
Attrition: 
n=23 (IG 
As per above. As per above n: 52 As per above CIN 
Incidence: 
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n=12; GC 
n=11) 
Female: n=83 
Age: mean 
55-58±11-12 
years 
Cancer: Not 
specified 
History of 
CINV: Yes 
Emetogenicity: 
19% high; 63% 
moderate 
 
Type: As per 
above, no placebo. 
Dose: 2g/d (8x 
0.25g) 
Duration: 3 days 
starting on day of 
CTx 
administration 
 
- <24hr post CTx (acute incidence): IG n=30/52; CG n=31/57; P=0.86 between groups 
- 24-48hr post CTx (delayed incidence): IG n=27/52; 31/57; P=0.16 between groups 
- Overall (mean of <24hrs and 24-48hrs):a IG n=29/52; CG n=31/57 
Severity (MANE Score; mean (SD); score ranges 1-7; higher score indicated more severe 
CIN): 
- <24hr post CTx, no aprepitant: IG 3.0 (1.1); CG 2.8 (1.3); P=0.47 
- <24hr post CTx, aprepitant: IG 2.8 (1.5); CG 3.1 (1.5); P=0.55 
- 24-48hr post CTx, no aprepitant: IG 3.2 (1.1); CG 3.0 (1.3); P=0.69 
- 24-48hr post CTx, aprepitant: IG 3.9 (0.9); CG 2.2 (0.7); P=0.01 
- Overall (mean of <24hr and 24-48hr scores):a IG 3.23 (1.15); CG 2.78 (1.2) 
- Acute Severity (mean of <24hr scores):a IG 2.9 (1.3); CG 2.95 (1.4) 
- Delayed Severity (mean of 24-48hr scores):a IG 3.55 (1); CG 2.6 (1) 
CIV 
Incidence: 
- 24hr post CTx (acute incidence): IG n=17/53; CG n=14/57; P=0.47 between groups 
- 24-48hr post CTx (delayed incidence): IG n=12/53; CG n=9/57; P=0.07 between groups 
- Overall Incidence (mean of <24hrs and 24-48hrs):a  IG n=15/53; CG n=12/57 
Severity (MANE Score; mean (SD); score ranges 1-7; higher score indicated more severe 
CIV): 
- 24hr post CTx, no aprepitant: IG 2.9 (0.9); CG 3.6 (1.4); P=0.61 
- 24hr post CTx, aprepitant: IG 3.7 (1.5); CG 4.0 (1.7); P=0.91 
- 24-48hr post CTx, no aprepitant: IG 3.7 (1.0); CG 4.0 (1.3); P=0.88 
- 24-48hr post CTx, aprepitant: IG 3.6 (1.3); CG 3.0 (0.0); P=0.77 
Adverse Events  
Occurring within the 3-day study period: 
- Fatigue: IG n=0/52; CG n=5/57; P=0.03 between groups 
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- Laboratory abnormalities: IG n=1/52; CG n=8/57; P=0.06 between groups 
- Miscellaneous: IG n=1/52; CG n=8/57; P=0.02 between groups 
Mortality 
Not reported 
 
CIN: chemotherapy induced nausea; CIV: chemotherapy induced vomiting; CINV: chemotherapy induced nausea and vomiting; CTx: chemotherapy; ESAS: Edmonton’s Symptom Assessment Scale; FACT-G: 
Functional Assessment of Cancer Therapy-General; GI: gastrointestinal; LS Mean: least squares mean; MANE: Morrow Assessment of Nausea and Emesis; N: number; RCT: Randomised Controlled Trial; RINVR: 
Rhodes Index of Nausea, Vomiting, and Retching; VAS: Visual Analogue Score 
a This was calculated by review authors to generate a number used for meta analyses. 
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Online Supplementary Material 4: Non-significant meta-analyses forest plots examining the 
efficacy and safety of ginger for ameliorating chemotherapy-induced nausea and vomiting 
 
Figure 1. Ginger supplementation of any dose or duration had no association with likelihood 
of overall nausea (OR: 0.84, 95% CI: 0.56-1.27; P=0.42; n=8 studies; n=9 interventions; n=928 
participants; I2=48%). 
 
 
 
 
 
Figure 2. Ginger supplementation of any dose or duration had no association with likelihood 
of overall nausea (OR: 0.97, 95% CI: 0.74-1.28; P=0.82; n=7 studies; n=8 interventions; n=883 
participants; I2=0%; GRADE level: moderate). Sensitivity analysis: studies with high risk of 
bias (>70% of Cochrane Risk of Bias domains rated as unclear or high risk of bias) deselected; 
sensitivity analysis according to dose (≤/>1g/day) or duration (≤/>3 days) did not result in 
significant findings. 
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Figure 3. Ginger supplementation of any dose or duration had no association with likelihood 
of overall nausea with subgroup analysis using the four categories outlined in the meta-analysis 
method of varied duration and dosage (OR: 0.85, 95% CI: 0.57-1.27; P=0.51; n=7 studies; n=8 
interventions; n=928 participants; I2=47%). 
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Figure 4. Ginger supplementation of any dose or duration had no association with likelihood 
of overall nausea with subgroup analysis using the four categories outlined in the meta-analysis 
method of varied duration and dosage (OR: 0.97, 95% CI: 0.74-1.28; P=0.76; n=7 studies; n=8 
interventions; n=883 participants; I2=0%). Sensitivity analysis: studies with high risk of bias 
(>70% of Cochrane Risk of Bias domains rated as unclear or high risk of bias) deselected. 
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Figure 5. Ginger supplementation of any dose or duration had no association with likelihood 
of acute nausea (OR: 0.81, 95% CI: 0.47-1.42; P=0.47; n=5 studies; n=6 interventions; n=590 
participants; I2=63%; GRADE level: very low). Sensitivity analysis according to dose 
(≤/>1g/day) or duration (≤/>3 days) did not result in significant findings.  
 
 
 
 
 
 
Figure 6. Ginger supplementation of any dose or duration had no association with likelihood 
of delayed nausea (OR: 0.92, 95% CI: 0.65-1.30; P=0.64; n=6 studies; n=7 interventions; 
n=834 participants; I2=28%; GRADE level: moderate). Sensitivity analysis according to dose 
(≤/>1g/day) or duration (≤/>3 days) did not result in significant findings. 
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Figure 7. Ginger supplementation of any dose or duration had no association with overall 
nausea severity (SMD: -0.09, 95% CI: -0.56-0.38; P=0.71; n=4 studies; n=5 interventions; 
n=438 participants; I2=83%). 
 
 
Figure 8. Ginger supplementation of any dose for any duration had no association with overall 
nausea severity (SMD: 0.18, 95% CI: -0.02-0.38; P=0.08; n=3 studies; n=4 interventions; 
n=378 participants; I2=0%; GRADE level: low). Sensitivity analysis: studies with high risk of 
bias (>70% of Cochrane Risk of Bias domains rated as unclear or high risk of bias) deselected; 
sensitivity analysis according to dose (≤/>1g/day) or duration (≤/>3 days) did not result in 
significant findings. 
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Figure 9. Ginger supplementation of any dose or duration had no association with acute nausea 
severity (SMD: -0.03, 95% CI: -0.22-0.16; P=0.76; n=4 studies; n=5 interventions; n=438 
participants; I2=0%). 
 
 
 
 
 
Figure 10. Ginger supplementation of any dose or duration had no association with acute 
nausea severity (SMD: 0.03, 95% CI: -0.17-0.23; P=0.79; n=3 studies; n=4 interventions; 
n=378 participants; I2=0%; GRADE level: low). Sensitivity analysis: studies with high risk of 
bias (>70% of Cochrane Risk of Bias domains rated as unclear or high risk of bias) deselected; 
sensitivity analysis according to dose (≤/>1g/day) or duration (≤/>3 days) did not result in 
significant findings.  
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Figure 11. Ginger supplementation of any dose or duration had no association with delayed 
nausea severity (SMD: 0.02, 95% CI: -0.62-0.67; P=0.94; n=4 studies; n=5 interventions; 
n=438 participants; I2=91%). 
 
 
 
 
Figure 12. Ginger supplementation of any dose or duration had no association with delayed 
nausea severity (SMD: 0.35, 95% CI: -0.07-0.77; P=0.10; n=3 studies; n=4 interventions; 
n=378 participants; I2=75%; GRADE level: very low).  Sensitivity analysis: studies with high 
risk of bias (>70% of Cochrane Risk of Bias domains rated as unclear or high risk of bias) 
deselected. 
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Figure 13. Ginger supplementation of any dose or duration had no association with likelihood 
of overall vomiting (OR: 0.78, 95% CI: 0.44-1.36; P=0.38; n=8 studies; n=9 interventions; 
n=825 participants; I2=66%; GRADE level: very low). 
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Figure 14. Ginger supplementation of varying dose and duration had no association with 
likelihood of overall vomiting with subgroup analysis (OR: 0.78, 95% CI: 0.44-1.36; P=0.27; 
n=8 studies; n=9 interventions; n=825 participants; I2=66%). 
 
 
 
 
 70 
 
Figure 15. Ginger supplementation of any dose or duration had no association with likelihood 
of acute vomiting (OR: 0.69, 95% CI: 0.38-1.24; P=0.22; n=6 studies; n=7 interventions; n=671 
participants; I2=57%; GRADE level: very low). 
 
 
 
 
 
Figure 16. Ginger supplementation of any dose or duration had no association with likelihood 
of delayed vomiting (OR: 0.83, 95% CI: 0.39-1.79; P=0.63; n=6 studies; n=7 interventions; 
n=671 participants; I2=76%; GRADE level: very low). 
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Figure 17. Ginger supplementation of varying dose and duration had no association with 
likelihood of delayed vomiting with subgroup analysis (OR: 0.83, 95% CI: 0.39-1.79; P=0.17; 
n=6 studies; n=7 interventions; n=671 participants; I2=76%).  
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Figure 18. Ginger supplementation of any dose for any duration had no association with quality 
of life (SMD: 0.47, 95% CI: -0.07-1.01; P=0.09; n=3 studies; n=3 interventions; I2=78%; 
n=279 participants; GRADE level: low). 
 
 
 
 
Figure 19. Ginger supplementation of any dose for any duration had no association with 
likelihood of heartburn (OR: 1.88, 95% CI: 0.68-5.18; P=0.22; n=3 studies; n=3 interventions; 
n=312 participants; I2=0%; GRADE level: low). 
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Figure 20. Ginger supplementation of any dose for any duration had no association with 
likelihood of fatigue (OR: 0.45, 95% CI: 0.13-1.61; P=0.22; n=3 studies; n=4 interventions; 
n=375 participants; I2=60%). 
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Online Supplementary Material 4: GRADE Assessment 
 
Table 1. GRADE assessment of ginger supplementation compared to placebo or standard care for chemotherapy-induced nausea and vomiting and related 
outcomes. 
 
 
Certainty assessment № of patients Effect 
Certainty 
№ of studies Study design 
Risk of 
bias Inconsistency Indirectness Imprecision 
Other 
considerations Ginger Placebo 
Relative 
(95% 
CI) 
Absolute 
(95% CI) 
Nausea Overall Incidence - Sensitivity Analysis (low risk of bias only, any duration, any dose) – Figure 2 of Online Supplementary Material 4 
8 
interventions 
(n=7 
studies)  
randomised 
trials  
not 
serious  
not serious  not serious  serious d none  246/430 
(57.2%)  
261/453 
(57.6%)  
OR 0.97 
(0.74 to 
1.28)  
7 fewer per 
1,000 
(from 75 
fewer to 59 
more)  
⨁⨁⨁◯ 
MODERATE  
Nausea Acute Incidence (any duration, any dose) – Figure 5 of Online Supplementary Material 4 
6 
interventions 
(n=5 
studies) 
randomised 
trials  
serious 
b 
serious c not serious  serious d none  158/289 
(54.7%)  
173/301 
(57.5%)  
OR 0.81 
(0.47 to 
1.42)  
52 fewer 
per 1,000 
(from 186 
fewer to 83 
more)  
⨁◯◯◯ 
VERY LOW 
Nausea Delayed Incidence (any duration, any dose) – Figure 6 of Online Supplementary Material 4 
7 
interventions 
(n=6 
studies)  
randomised 
trials  
not 
serious  
not serious  not serious  serious d none  238/410 
(58.0%)  
252/424 
(59.4%)  
OR 0.92 
(0.65 to 
1.30)  
20 fewer 
per 1,000 
(from 107 
fewer to 61 
more)  
⨁⨁⨁◯ 
MODERATE  
Nausea Overall Severity - Sensitivity Analysis (low risk of bias only, any duration, any dose) – Figure 8 of Online Supplementary Material 4 
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Certainty assessment № of patients Effect 
Certainty 
№ of studies Study design 
Risk of 
bias Inconsistency Indirectness Imprecision 
Other 
considerations Ginger Placebo 
Relative 
(95% 
CI) 
Absolute 
(95% CI) 
4 
interventions 
(n=3 
studies) 
randomised 
trials  
not 
serious  
not serious  not serious  very serious 
a 
none  142  150  -  SMD 0.18 
higher 
(0.02 lower 
to 0.38 
higher)  
⨁⨁◯◯ 
LOW  
Nausea Acute Severity - Sensitivity Analysis (low risk of bias only, any duration, any dose) – Figure 10 of Online Supplementary Material 4 
4 
interventions 
(n=3 
studies)  
randomised 
trials  
not 
serious  
not serious  not serious  very serious 
a 
none  185  193  -  SMD 0.03 
SD higher 
(0.17 lower 
to 0.23 
higher)  
⨁⨁◯◯ 
LOW  
Nausea Delayed Severity - Sensitivity Analysis (low risk of bias only, any duration, any dose) – Figure 12 of Online Supplementary Material 4 
4 
interventions 
(n=3 
studies) 
randomised 
trials  
not 
serious  
serious c not serious  very serious 
a 
none  185  193  -  SMD 0.35 
SD higher 
(0.07 lower 
to 0.77 
higher)  
⨁◯◯◯ 
VERY LOW  
Vomiting Overall Incidence (any duration, any dose) – Figure 13 of Online Supplementary Material 4 
9 
interventions 
(n=8 
studies) 
randomised 
trials  
not 
serious 
serious c not serious  very serious 
d 
none  130/407 
(31.9%)  
150/418 
(35.9%)  
OR 0.78 
(0.44 to 
1.36)  
55 fewer 
per 1,000 
(from 163 
fewer to 74 
more)  
⨁◯◯◯ 
VERY LOW 
Vomiting Acute Incidence (any duration, any dose) – Figure 15 of Online Supplementary Material 4 
 76 
Certainty assessment № of patients Effect 
Certainty 
№ of studies Study design 
Risk of 
bias Inconsistency Indirectness Imprecision 
Other 
considerations Ginger Placebo 
Relative 
(95% 
CI) 
Absolute 
(95% CI) 
7 
interventions 
(n=6 
studies) 
randomised 
trials  
serious 
q 
serious e not serious  very serious 
d 
none  79/330 
(23.9%)  
100/341 
(29.3%)  
OR 0.69 
(0.38 to 
1.24)  
71 fewer 
per 1,000 
(from 157 
fewer to 47 
more)  
⨁◯◯◯ 
VERY LOW 
 
Vomiting Acute Incidence – Subgroup Analysis (>3-days duration, ≤1g/day) – Figure 3 of Manuscript 
3 
interventions 
(n=3 
studies) 
randomised 
trials  
not 
serious  
not serious  not serious  serious a none  14/151 
(9.3%) 
33/150 
(22.0%) 
OR 0.37 
(0.17 to 
0.81) 
126 fewer 
per 1,000 
(from 174 
fewer to 34 
fewer) 
⨁⨁⨁◯ 
MODERATE 
Vomiting Delayed Incidence (any duration, any dose) – Figure 16 of Online Supplementary Material 4 
7 
interventions 
(n=6 
studies) 
randomised 
trials  
serious 
s 
serious e not serious  serious a none  101/330 
(30.6%)  
113/341 
(33.1%)  
OR 0.83 
(0.39 to 
1.79)  
1 fewer per 
1,000 
(from 2 
fewer to 0 
fewer)  
⨁◯◯◯ 
VERY LOW 
Quality of Life Score (any duration, any dose) – Figure 18 of Online Supplementary Material 4 
3 
interventions 
(n=3 
studies) 
randomised 
trials  
not 
serious  
serious c not serious  serious a none  117  111  -  SMD 0.47 
SD higher 
(0.07 lower 
to 1.01 
higher)  
⨁⨁◯◯ 
LOW 
Fatigue Incidence (Sensitivity Analysis - ≤3-days, any dose) – Figure 4 of Manuscript 
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Certainty assessment № of patients Effect 
Certainty 
№ of studies Study design 
Risk of 
bias Inconsistency Indirectness Imprecision 
Other 
considerations Ginger Placebo 
Relative 
(95% 
CI) 
Absolute 
(95% CI) 
2 
interventions 
(n=1 study) 
randomised 
trials  
not 
serious  
not serious  not serious  very serious 
a 
none  1/105 
(1.0%)  
10/114 
(8.8%)  
OR 0.15 
(0.03 to 
0.87)  
74 fewer 
per 1,000 
(from 85 
fewer to 65 
more)  
⨁⨁◯◯ 
LOW  
Any Adverse Effects Incidence (any duration, any dose) – Figure 5 of Manuscript 
5 
interventions 
(n=3 
studies) 
randomised 
trials  
not 
serious  
not serious  not serious  serious a none  96/725 
(13.2%)  
58/733 
(7.9%)  
OR 2.03 
(1.39 to 
2.99)  
69 more 
per 1,000 
(from 28 
more to 125 
more)  
⨁⨁⨁◯ 
MODERATE  
Heartburn Incidence (any duration, any dose) – Figure 19 of Online Supplementary Material 4 
3 
interventions 
(n=3 
studies) 
randomised 
trials  
not 
serious  
not serious  not serious  very serious 
a 
none  13/157 
(8.3%)  
6/155 
(3.9%)  
OR 1.88 
(0.68 to 
5.18)  
32 more 
per 1,000 
(from 12 
fewer to 
134 more)  
⨁⨁◯◯ 
LOW  
CI: Confidence interval; OR: Odds ratio; SMD: Standardised mean difference 
Explanations 
a. Wide CI; small sample size and small number of events.  
b. 2/6 studies rated 'unclear' and 1/6 'high' for random sequence generation bias; 4/6 'unclear' and 1/6 'high' for allocation concealment bias.  
c. Large variation in effect size; minimal overlap in confidence intervals; I2 high; P<0.05.  
d. Moderately wide CI's  
e. 5/5 studies rated 'unclear' risk of bias and 1/5 'high' for allocation concealment, however, unlikely to largely affect outcomes.  
f. 1/4 studies rated 'unclear' and 1/4 studies rated 'high' for random sequence generation bias; 2/4 rated 'unclear' and 1/4 rated 'high' for allocation concealment 
bias.  
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g. 1/4 studies rated 'unclear' and 1/4 'high' for random sequence generation bias; 3/4 'unclear' and 1/4 'high' for allocation concealment bias.  
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